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THE ROLE OF THE NUCLEOLUS IN NEURODEGENERATION 
Justin L. Hallgren 
August 26, 2014 
 The overarching goal of my studies was to determine the role of the nucleolus in 
neurodegenerative disease.  Numerous studies suggest the impairment of ribosomal 
biogenesis in neurodegenerative disease and such a condition may contribute to neuronal 
dysfunction in two ways, loss of function and stress response.  Ribosomal biogenesis has 
been demonstrated to play an essential role in both neuronal growth and maintenance.  
Therefore insufficient levels of ribosomal biogenesis would be expected to produce 
atrophy and synapse loss.  Moreover, the fidelity of ribosomal biogenesis is monitored by 
nucleolar and ribosomal stress responses which induce apoptosis and/or cell cycle arrest.  
Therefore, I have reviewed the literature demonstrating nucleolar involvement in 
neurodegeneration and investigated three important aspects of nucleolar dysfunction 
which are relevant to both general mechanisms of neuronal death and specifically 
neurodegenerative disease. 
 The studies contained in this document address four important questions 
regarding the nucleolus and neurodegeneration.  First, is rDNA content stable throughout 
aging?  Second, is increased rDNA promoter methylation specific to Alzheimer’s 
disease?  Third, are human brain tissue-based assessments of nucleolar stress
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 mechanistically feasible?  Fourth, is RPL11 a bona fide nucleolar and ribosomal stress 
mediator in primary cortical neurons? 
 I demonstrate several important results.  rDNA content is stable throughout aging 
and increased rDNA promoter methylation appears to be specific to Alzheimer’s disease.  
Nucleolar stress markers are at least moderately stable in the mammalian post mortem 
brain.  Lastly, RPL11 is indeed a bona fide mediator of nucleolar stress, ribosomal stress 
and neuronal death. 
 Three conclusions contained in this document provide a foundation for future 
studies investigating nucleolar and ribosomal stress in neurodegenerative disease.  First, I 
provided weight of evidence support for the validity of post mortem brain tissue-based 
studies.  Second, the identification of bona fide stress mediators is an essential step for 
designing novel therapeutic interventions.  Lastly, my results suggest that in primary 
neurons RPL11-mediated stress does not require catastrophic inhibition of RNA 
Polymerase I.  Therefore, RPL11-mediated stress may indeed be a significant contributor 
to neurodegeneration despite the lack of canonical nucleolar stress markers. 
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 While Wagner is believed to be the first person to formally describe the nucleolus 
in 1835, it was Gabriel Valentine who first described it in neurons one year later [91, 
201].  The nucleolus is a non-membrane bound organelle that forms over the rDNA-
containing nucleolar organizer regions [59].  Interestingly, the nucleolus has been 
referred to as “an organelle formed by the act of building a ribosome” [171].  Such a 
description is based on findings which suggest that RNA Polymerase I mediated 
transcription is necessary for its assembly [171]. 
 While many think of the nucleolus as simply a ribosome factory, a considerable 
amount of evidence suggests it has important roles in numerous other cellular functions 
[91].  Perhaps the most exciting of these non-canonical functions is its role in stress 
response [91, 162].  The nucleolus possess the ability to sequester numerous proteins 
within its borders, including but not limited to stress mediators and cell cycle regulators 
[202].  Impairment of RNA Polymerase I is sufficient to induce changes in nucleolar 
morphology which allow for the escape of these previously sequestered stress mediators.  
In addition to stress response, recent literature suggests that the nucleolus also regulates 
total cellular transcription through modulation of global heterochromatin content and 
cellular metabolism through interactions with p53 [145, 195].  Lastly, the nucleolus is 
known to facilitate the processing of non-ribosomal RNAs and contribute to the assembly
2 
 
 of ribonucleoprotein complexes such as U6 and the signal recognition particle (SRP) 
[208].  Thus, the nucleolus appears to be significantly more than just a ribosome factory. 
 rDNA is unlike other portions of the genome.  Ribosomal biogenesis begins with 
RNA Pol I transcribing the 47S pre-rRNA and importantly this is believed to be the rate 
limiting step in ribosomal biogenesis [82, 163].  To accommodate protein synthesis 
demands, cells evolved to have hundreds, and in some cases thousands, of rDNA copies 
[76, 163].  The diploid human genome contains approximately 600 copies of rDNA, but, 
interestingly, this number is subject to considerable inter-individual variability [233].  
The rDNA units are arranged as tandem repeat head-to-tail arrays on the short arms of the 
5 acrocentric chromosomes [236].  Surprisingly, at any given time, only about half of the 
cells total rDNA copies are believed to be active [76, 233]. 
 The 47S pre-rRNA is transcribed as one continuous transcript containing the 18S-
, 5.8S-, and 28S-rRNAs along with 4 spacers regions[76] (Fig.1).  Two of these spacers, 
the internal transcribed spacers 1 and 2 (ITS1 and ITS2) are interspersed between the 
three rRNAs [81].  The other two spacers, the 5’- and 3’-external transcribed spacers 
(5’ETS and 3’ETS), are located on the extreme upstream and downstream ends of the 
transcript.  The last ribosomal RNA, the 5S rRNA is transcribed outside the nucleolus by 
RNA Polymerase III [199].  All of the approximately 80 ribosomal proteins are 
transcribed in the nucleus by RNA Polymerase II, translated in the cytoplasm, and 
trafficked back to the nucleolus for ribosomal assembly [163]. Ribosome assembly 
begins in the nucleus.  Prior to large subunit assembly, RPL5, RPL11 and the 5S RNA 




Figure 1. Depiction of a canonical ribosomal DNA Array. 
rDNA units are arranged as tandem head-to-tail arrays.  The transcribed region is illustrated by the thick 
red line.  Ribosomal RNAs are depicted by rectangles.  The transcribed region contains 4 spacers, which 
are removed during pre-rRNA processing, and 3 ribosomal RNAs.  The last ribosomal RNA, 5S, is 




particle (5S RNP) [225].  Importantly, this sub complex has been implicated in the 
ribosomal stress response [24, 64].  The 5S RNP then joins with the 5.8S and 28S rRNAs 
and the remaining large subunit ribosomal proteins (RPLs) to form the large subunit.  The 
18S rRNA and the small ribosomal subunit proteins (RPSs) join to form the small 
subunit.  Both subunits are trafficked out of the nucleus by chromosome region 
maintenance 1 (CRM1) mediated nuclear export and are chaperoned by nucleophosmin 
[104].  Interestingly, the export mechanism for each subunit is not identical as exportin 5 
(EXP5) is necessary for export of the large subunit, but not the small subunit [255].  
Lastly, the joining of the two subunits occurs in the cytoplasm [91]. 
 Ribosomal biogenesis is dynamically regulated on multiple levels by a number of 
factors including nutrient availability, oncogenes, growth factors, tumor suppressors, 
genotoxic stress, starvation, metabolic stress, and viral infection [76].  In general, stimuli 
that increase metabolism or promote growth will enhance ribosomal biogenesis.  
Conversely, signals which decrease metabolism or growth will inhibit ribosomal 
biogenesis [126, 182, 260].  The master regulator for this process appears to be RNA 
Polymerase I as early studies have determined this to be the rate limiting step in 
ribosomal biogenesis [163].  In support of Pol I as the master regulator, unbound 
ribosomal proteins have been linked to the inhibition of their own translation through a 
p53- phosphatase and tensin homolog (PTEN)-mammalian target of rapamycin (mTOR)  
cascade [44, 96, 213].  Thus, ribosomal proteins appear to adjust their production based 
on the availability of pre-rRNA and not vice versa. 
 Regulation of pre-rRNA production is believed to happen in two ways, first 
through modulating the activity of RNA Polymerase I and second by modulating the 
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number of active rDNA copies [76].  Not surprisingly, regulation of RNA Polymerase I 
activity is an especially intricate and convoluted process with connections to numerous 
kinases, phosphatases, tumor suppressors, and oncogenes converging on many of its 
cofactors either altering their levels of expression or changing their activity through post-
translational modification [76].  Traditionally, it was believed that modulating RNA 
Polymerase I activity was responsible for transient changes in activity, such as in 
response to nutrient availability, whereas alteration in the number of active rDNA copies 
was reserved for long term conditions such as following cell differentiation.  However, 
recent studies suggest this may not be the case.  For example, epigenetic silencing of 
rDNA copies was shown to occurs in response to low cellular energy levels [182, 260]. 
 Ribosomal biogenesis is believed to be the number one consumer of cellular 
energy in rapidly dividing cells [113].  Building a ribosome is an enormous task which 
requires the concerted effort of all three RNA polymerases to produce approximately 80 
ribosomal proteins, 200 non-ribosomal proteins, 4 large ribosomal RNAs and 75 small 
nucleolar RNAs [62, 124, 163].  To give perspective, in yeast RNA Polymerase I is 
believed to account for 60% of total cellular transcription [250].  Moreover,  at any given 
time, ribosomal RNA can account for as much as 80% of total cellular RNA, with tRNAs 
and mRNAs accounting for 15% and 5%, respectively [250].  Thus, ribosomal biogenesis 
is a major undertaking which consumes enormous amounts of cellular resources. 
 Given the extensive transcriptional and energetic commitment, cells have evolved 
a ribosomal stress response for monitoring the fidelity of ribosome synthesis.  
Traditionally, the field has used the term nucleolar stress to refer to nucleolar 
disintegration and perturbed ribosomal biogenesis.  However, current reports suggest that 
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nucleolar disintegration and perturbed ribosomal biogenesis are not synonymous.  
Ribosomal biogenesis can be perturbed in many ways which do not cause nucleolar 
disintegration.  Thus, it is important to differentiate between the concepts of nucleolar 
stress and ribosomal stress (Fig.2). 
 In general, the term nucleolar stress describes an inhibition of RNA polymerase I 
which disrupts nucleolar morphology and triggers a p53 mediated stress response.  
However, over the last decade it has become apparent that the p53 response is centered 
on stoichiometric errors in ribosome assembly [44, 114].  Essentially, “extra-ribosomal” 
ribosomal proteins, meaning ribosomal proteins which are not incorporated into the 
ribosome, may be recruited to perform various “extra-ribosomal” functions [251].  The 
most extensively documented of these extra-ribosomal functions is the inhibition of the 
p53 negative regulator mouse double minute homologue 2 (MDM2) by the ribosomal 
proteins L5 and L11 [24, 63, 64]. However, numerous other extra-ribosomal functions 
have been described in the literature [251]. 
 In addition to nucleolar stress-associated reductions of rRNA there are several 
additional mechanisms for disrupting stoichiometry of ribosomal biogenesis (Fig.3).  
Therefore, ribosomal stress is a separate entity from the canonical concept of nucleolar 
stress.  Haploinsufficiency of a single ribosomal protein gene is one such mechanism and 
is linked to diseases such as Diamond Blackfan anemia and 5q- Syndrome.  Oncogenic 
signaling may be a third possibility [114, 153].  The ribosomal stress pathway appears to 
be tumor suppressive as mice lacking ribosomal protein-MDM2 interaction display 




Figure 2. Overlap of the nucleolar and ribosomal stress responses. 
The ribosomal stress response is depicted within the blue/gray oval.  The nucleolar stress response is 
contained within the orange/tan oval.  In many cell types, ribosomal stress without nucleolar disruption 
triggers a non-apoptotic accumulation of p53.  Numerous stress mediators are sequestered inside the 
nucleolus, but are released following inhibition of RNA polymerase I.  One such mediator, MYB binding 
protein 1A is known to acetylate p53 altering the spectrum of its target genes and switching the p53 





Figure 3. Potential inducers of ribosomal stress. 
Multiple mechanisms for altering ribosomal stoichiometry are possible.  The canonical model of nucleolar 
stress is centered on inhibition of RNA polymerase I, but impairment of pre-rRNA processing and 
haploinsufficiency of ribosomal protein genes are also well documented mechanisms for altering ribosomal 
stoichiometry.  Preliminary evidence suggests oncogenic signaling also engages the ribosomal stress 
response.  Lastly, aneuploidy has been hypothesized to alter the stoichiometry of ribosomal components, 




Myc driven oncogenesis engages the ribosomal stress response in some manner.  Thus, it 
is likely that oncogenic stimuli and Myc overexpression in particular, disproportionately 
stimulates production of certain ribosomal components relative to others.  In support of 
this concept, a constitutively active variant of the oncogene Harvey Rat Sarcoma Viral 
Oncogene Homolog (HRAS), was shown to stimulate the production of 47S pre-rRNA in 
excess of the cells capacity for processing [187].  Such a condition induced p53 mediated 
senescence and was rescued by overexpression of several processing proteins.  While it 
was not shown explicitly, this strongly suggests cells contained insufficient quantities of 
mature rRNA species relative to ribosomal proteins.  A fourth possibility is aneuploidy 
[114].  To date, 14 ribosomal proteins are known to bind MDM2 and importantly they are 
dispersed throughout the genome [114].  Such a distribution may enable a ribosomal 
stress-mediated p53 response in aneuploid cells.  Therefore, stoichiometric imbalances of 
ribosomal components can be generated by numerous mechanisms that are independent 
of RNA Polymerase I.  Thus, nucleolar disruption is sufficient, but not necessary to 
induce ribosomal stress.  Additionally, nucleolar stress may involve numerous stress 
mediators not seen with other inducers of ribosomal stress due to failure of nucleolar 
sequestration.  For example, the protein Myb binding protein 1 A (MYBBP1A) exits the 
nucleolus during nuclear stress and acetylates p53 [125].  Interestingly, the nucleolar 
structure also excludes the entrance of some stress mediators as the tumor suppressor 
p19-alternate reading frame (ARF) enters the nucleolus upon nucleolar stress [225]. 
 The mechanisms of ribosomal protein-MDM2-p53 interactions are only partially 
understood. While it appears that the 5S RNP is potentially the major mediator, many 
other ribosomal protein have been reported as MDM2 binding partners [24, 49, 63, 64].  
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As stated previously, 14 ribosomal proteins have been identified as binders of MDM2 
and some have speculated that this number is an underestimate [114].  MDM2 ribosomal 
protein binding locations appear to be determined  by acid base mediated protein-protein 
interactions [114].  Thus with 80 ribosomal proteins, the majority of which are highly 
basic, there is opportunity for more. 
 Some have questioned the physiological relevance of some ribosomal protein-
MDM2 interactions [24].  Many of these interactions have been identified in 
overexpression studies and thus may represent experimental artifact [41, 146, 157, 264].  
In support of this concept, two studies using different methods to impair ribosomal 
biogenesis both demonstrated that only RPL5 and RPL11 are absolutely necessary for 
p53 stabilization, suggesting that they alone are the master mediators[24, 64].  Moreover, 
Bursac et.al. (2012) demonstrated that following nucleolar disruption unbound ribosomal 
proteins are rapidly degraded by the proteasome [25].  In support of this finding, the 
Lamond laboratory has reported persistent proteasome-mediated degradation of excess 
ribosomal proteins under basal unstressed conditions[131].  Conversely, RPL5 and 
RPL11 escaped this degradation by co-dimerization [25].  Therefore, the buildup of 
“extra-ribosomal” ribosomal proteins other than RPL5 and RPL11 appears unlikely under 
physiological conditions.  However on the other hand, three MDM2-interacting 
ribosomal proteins have been shown to produce differential effects on the transcription of 
p53 target genes [40].  Thus, the relevance of other ribosomal proteins is still under 
debate. 
 Interestingly, impairment of either the large- or the small subunit was shown to 
produce separate responses, which were additive upon co-occurrence [64].  In the case of 
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the large subunit, free RPL5 and RPL11 were generated by the expected stoichiometric 
imbalances of ribosomal proteins.  Surprisingly, in the case of disrupted synthesis of the 
small subunit accumulation of p53 was achieved through increased translation of 5′ 
terminal oligopyrimidine tract (5’TOP) mRNAs, which include RPL5 and RPL11 [64].  
Such findings raise several interesting questions.  First, are unbound ribosomal proteins 
always degraded by the proteasome or is this a feature specifically induced by nucleolar 
stress?  If it is indeed nucleolar disruption specific, this increases the likelihood that 
additional ribosomal proteins are stress effectors.  Second, if RPL5 and RPL11 levels can 
be increased in the absence of nucleolar disruption or large subunit impairment, could 
other stressors be converging on this mechanism?  Third, given that RPL5 and RPL11 are 
necessary for p53 induction and the fact that other ribosomal protein-MDM interactions 
have produced differential effects on the expression of p53 target genes, could there be 
different outcomes of ribosomal stress dependent on which RPs are primary stress 
mediators [40, 64]? 
 The neuronal nucleolus plays major roles in cell growth, maintenance and repair.  
Thus in addition to the ribosomal stress response one must also consider loss of these 
functions as a possible contributor to neurodegeneration.  Brain derived neurotrophic 
factor (BDNF) is a known inducer of both ribosomal biogenesis and neuronal growth.   It 
has been shown that ongoing transcription of 47S pre-rRNA is necessary for BDNFs 
morphogenic effect on hippocampal neurons [72].  BDNF treatment was shown to 
significantly increase neurite length, neurite branching, and cell body volume and these 
increases were prevented after shRNA mediated knockdown of the RNA Polymerase I 
cofactor Transcription Initiation Factor 1A (TIF-1A).  Importantly, these effects were not 
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due to p53 signaling or impairment of total cellular translation.  Taken together, these 
observations suggest that the rate of ribosomal biogenesis regulates neuronal size.  
Therefore, given the importance of ribosomal biogenesis for growth and maintenance of 
neurites suboptimal levels of ribosomal biogenesis may result in neuronal atrophy and 
synapse loss. 
 Similarly, increased rates of ribosomal biogenesis have been connected to a 
neuron’s ability to regenerate after injury.  In a series of related reports the Jones 
laboratory investigated nucleolar function in regeneration competent facial motor neurons 
and regeneration incompetent rubrospinal neurons [115, 116, 231].  Their data suggest 
that both classes of neurons experience stalled pre-rRNA processing and possibly 
increased RNA polymerase I activity following axotomy.  In the case of regeneration 
component neurons the inhibition of rRNA processing was transient and ribosome 
content increased acutely [115, 116].  Moreover, treatment with testosterone decreased 
the duration of processing impairment and further augmented recovery.  Conversely, 
regeneration incompetent neurons did not experience any increases in ribosome content 
and testosterone had no effect on regeneration [231].  Thus, robust levels of ribosomal 
biogenesis are implicated in neuronal regeneration. 
 A substantial amount of evidence suggests that nucleolar dysfunction is present in 
human neurodegenerative diseases. In some cases one disease may engage multiple anti-
nucleolar/anti-ribosomal mechanisms suggested while in other cases similar mechanism 
may compromise ribosomal biogenesis in multiple pathologies.  In the sections which 
follow, I will review the literature that presents evidence of nucleolar involvement in the 




 Nucleolar dysfunction is documented in both Parkinson’s disease (PD) patients 
and animal models of PD.  The size of the nucleolus is believed to be directly related to 
the amount of pre-rRNA stored within its borders[202].  Provided there is no impairment 
of processing, nucleolar size is a direct reflection of RNA Polymerase I activity.  
Decreased nucleolar volume has been documented in human PD tissue and two 
pharmacological PD models, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 
6-hydroxydopamine (6-OHDA) [88, 156, 214].  In addition, increased frequency of 
dopaminergic neurons with  dispersion of nucleolar nucleophosmin, (NPM1) was 
observed  in substantia nigra from PD brains as compared to controls [214].  Moreover, 
decreased expression of nucleolin, a protein necessary for ribosomal biogenesis, has been 
detected in both PD brain and the rotenone pharmacological model [32].  Lastly, 
angiogenin, which has been suggested to be a disease modifier in PD, is known to 
promote RNA Polymerase I activity and its overexpression was shown to be protective in 
two out of three pharmacological PD models[229, 230]. 
 Two genes commonly mutated in PD have direct connections to the nucleolus.  
Mutant DJ-1 aggregates have been shown to sequester TRAF and TNF Receptor 
Associated Protein (TTRAP) [247].  TTRAP is necessary for pre-rRNA processing and 
its entrapment in cytoplasmic aggregates prevents its nucleolar localization thus 
decreasing ribosomal biogenesis.  Mutant Parkin is unable to bind the Parkin Interacting 
Substrate (PARIS) [107].  Unbound PARIS is then free to decrease rDNA transcription 
through interactions with the nucleolar protein MYB binding protein 1a (MYBBP1a), 
polymerase-associated factor 53 (PAF53), and the rDNA promoter. 
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 In an attempt to determine the contribution of nucleolar stress to PD pathology 
Rieker et. al. generated a transgenic mouse model which contained floxed alleles for TIF-
1A and crossed it with a mouse expressing tamoxifen inducible cre-recombinase under 
the control of the dopamine transporter promoter (TIF-IA
DATCreERT2
) [214].  As TIF-1A is 
necessary for RNA Polymerase I activity, the authors could induce nucleolar disruption 
specifically in the dopaminergic neurons of adult mice. 
 Interestingly, TIF-IA
DATCreERT2
 mice developed a PD-like pathology upon deletion 
of TIF1A.  With regards to cell signaling, both human PD and the TIF-IA
DATCreERT2 
mouse model have increased p53 signaling, decreased mTOR activity, and the 
accumulation of oxidative stress.  With regards to pathology, the TIF-IA
DATCreERT2 
mouse 
presented with anatomical susceptibility similar to that of human PD, as dopaminergic 
neurons of the substantia nigra were considerably more sensitive than those contained in 
the ventral tegmental area.  Moreover, TIF-IA
DATCreERT2
 mice experienced a prolonged 
chronic degeneration and reproduced motor deficits seen in other animal models of PD.  
Interestingly in the mouse model, adult dopaminergic neurons did not undergo acute 
apoptosis following loss of RNA Polymerase I activity and experienced a prolonged 
degeneration. 
 While the upstream mechanisms initiating PD are only partially understood, the 
general consensus is that the end result is death of dopaminergic neurons in the substantia 
nigra.  Multiple pharmacological models, including dopamine, 6-OHDA, MPTP, and 
rotenone all strongly suggest p53 and caspase mediated apoptosis as the predominant 
source of neuronal death [139].  However, it should be noted that attempts to determine 
p53 mediated apoptosis in post mortem tissue have produced mixed results.  Several 
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studies attempting to detect apoptosis by assessing DNA fragmentation in neurons have 
produced negative results [14, 101, 121].  However, two studies using more sensitive 
methods were successful at detecting apoptotic neurons [176, 241]  These struggles 
should not be surprising as neuronal death in PD occurs over decades, and typical 
apoptosis is initiated and executed over several hours or days.  Thus, at any given time 
very few, if any, neurons are actually in the act of dying. 
 Molecular studies aimed at detecting apoptosis sensitizing proteins have been far 
more convincing, as significant increases have been detected for p53, its pro-apoptotic 
target gene, BCL2-associated X protein (BAX), and a pro-apoptotic active p38 mitogen-
activated protein kinase (MAPK) [43, 85, 108, 177, 242].  Moreover, multiple studies 
have detected activation of apoptosis-associated caspases 3, 8, and 9 in PD compared to 
age matched controls [5, 84, 86].  Thus while it may be premature to say that apoptosis is 
major mode of neuronal loss in PD, there is considerable evidence that the pro-apoptotic 
arm of the p53 signaling is activated. Therefore, lack of apoptosis in TIF1A mouse model 
of PD suggests that it does not represent all pathological components of human PD. 
 Interestingly as part of the TIF-IA
DATCreERT2
 transgenic mice study, the authors 
stumbled upon an important link between nucleolar stress and oxidative stress.  These 
two stressors appear to have a cyclical relationship as each one appears capable of 
inducing the other.  TIF-IA
DATCreERT2
 transgenic mice had severely compromised 
mitochondrial function as determined by multiple parameters, including gene expression, 
enzymatic activity and markers of oxidative damage [214].  Expression of the 
transcription factor Yin-Yang 1 (YY1), which stimulates the transcription of multiple 
mitochondrial proteins, was decreased approximately 40% in mixed tissue samples.  
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Additionally, the YY1 target gene uncoupling protein 2 (UCP2) was also significantly 
reduced.  Neuron specific measurement of cytochrome C oxidase activity was decreased 
approximately 40%.  Additionally, 4 weeks after tamoxifen treatment the frequency of 
neurons which contained markers of oxidative damage, including tyrosine nitrosylation, 
8-Oxo-2'-deoxyguanosine (8-OHdG), and neuroketals, were increased several fold.  
Taken together these data strongly suggest that nucleolar stress is sufficient to 
compromise mitochondrial function and induce oxidative stress.  Interestingly, the 
oxidative stress based MPTP pharmacological model of PD also produced significant 
deficits in nucleolar function, as determined by decreased 47S pre-rRNA levels, 
increased NPM dispersion and decreased p-RPS6.  Thus, nucleolar stress and oxidative 
stress appear to reciprocally regulate one another. 
Poly Glutamine Diseases- Huntington’s-Disease, Machado-Joseph’s-Disease, and 
Several Spinal Cerebellar Ataxias 
 Lee et.al. (2011) demonstrated for the first time that pre-rRNA levels were 
significantly decreased in the R6/2 Huntington’s Disease (HD) mouse model [135].  This 
finding would later be independently verified by two other laboratories [214, 245].  
Additionally, they showed that protein levels of the RNA Polymerase I cofactor upstream 
binding factor (UBF) were also reduced in both R6/2 mice and human striatal tissue.  
Interestingly, UBF mRNA levels were not decreased suggesting that HD pathology may 
preferentially decrease its protein stability.  Moreover, the ability of ectopically expressed 
UBF to stimulate transcription was reduced in cell lines expressing mutant huntingtin 
(htt)-Q111, but not htt-Q7 controls, suggesting that an upstream regulator of UBF was 
impaired in HD.  Using both cell lines and animal models, the authors showed that CREB 
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binding protein (CBP) had decreased levels and a portion was also sequestered in htt 
aggregates.  Moreover, they demonstrated that CBP mediated acetylation of UBF was 
necessary for RNA Pol I transcriptional activity and importantly, acetylation was 
significantly decreased in HD models.  Taken together these findings support a model 
where HD aggregates sequester CBP preventing it from acetylating UBF which 
subsequently inhibits ribosomal biogenesis.  Interestingly, in a follow up article this same 
group demonstrated that silencing of UBF through ESET mediated trimethylation is also 
up regulated in HD cell lines [94]. 
 Tsoi et.al. (2012) focused almost exclusively on the CAG expansion in the 
Machado-Joseph’s Disease gene (MJD), but their work also suggests that CAG expansion 
toxicity is “motif” specific and toxicity is independent of the gene where it is located 
[245].  This suggests MJD, HD, and CAG associated spinal cerebellar ataxias all contain 
the same pathological mechanism.  Ribosomal biogenesis appears to be significantly 
reduced in MJD flies as both pre-rRNA levels were significantly reduced and rDNA 
promoter methylation, which is a biomarker for inactivity, was significantly increased.  
Moreover, RPL5, RPL11 and RPL23 were shown to be in complexes with MDM2.  It is 
well documented that nucleolar stress activates p53 mediated apoptosis via ribosomal 
protein mediated inhibition of MDM2.  Indeed, p53 mediated apoptosis was activated in 
response to CAG expansion in MJD flies, as determined by increased p53 expression, the 
appearance of cytosolic cytochrome C, and activated caspase 3. 
 The mechanism of MJD-associated ribosomal stress appears to be strictly RNA 
mediated and involves sequestration of the RNA Polymerase I cofactor nucleolin.  This 
was determined in two ways.  First, CAGCAA repeats which code for identical proteins 
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did not produce toxicity.  Second, CAG expansion in the 3’ untranslated region of a GFP 
vector still produced toxicity.  Pull down experiments demonstrated that CAG RNAs 
were binding and sequestering nucleolin.  In support of this concept, MJD cells displayed 
decreased binding of nucleolin to the rDNA gene upstream control element.  Thus, if 
deficiencies in nucleolin activity were responsible for the pathology seen in MJD, 
overexpression would be expected to produce a significant rescue.  Indeed, nucleolin over 
expression reduced apoptosis and returned pre-rRNA to control levels.  Interestingly, a 
similar mechanism has been implicated in chromosome 9 open reading frame 72 
(C9ORF72) hexanucleotide expansion linked Amyotrophic Lateral Sclerosis (ALS) and 
Frontotemporal Dementia (FTD) [79]. 
 Despite focusing primarily on the contribution of nucleolar disruption to HD 
pathology through the use of striatum specific induction of nucleolar stress, Kreiner et.al. 
(2013) still expanded upon the other studies claiming nucleolar stress in the R6/2 HD 
mouse model [122].  In addition to reproducing the pre-rRNA deficits seen by others, 
they demonstrated that the frequency of neurons with dispersed nucleophosmin was also 
significantly increased at time points occurring prior to the induction of neuronal death.  
Additionally at 13 weeks, total cellular 18S rRNA was decreased approximately 60% 
suggesting that cellular ribosome content was substantially reduced. 
 The authors generated a transgenic mouse line (TIF-IA
D1RCre
) which contained 
genetic inactivation of TIF-1A in medium spiny neurons by crossing TIF-IA
flox/flox 
mice 




phenocopied many aspects of the R6/2 HD mouse.  Abnormal posture and 
gait were evident at 40 weeks of age.  As early as 16 weeks, more subtle differences such 
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as increased feet clasping behavior and decreased rotarod performance were evident. TIF-
IA
D1RCre 
mice also experienced increased p53 and oxidative damage [122].  Gliosis 
occurred sometime between 9 and 13 weeks of age.  As the TIF-IA
D1RCre
 mice modeled 
several functional and pathological elements of HD, large scale gene expression changes 
were also investigated.  Microarray data from TIF-IA
D1RCre
 mice were compared against 
published mRNA profiles of R6/2 mice and early stage human HD.  When considering 
the top 250 upregulated and downregulated genes, TIF-IA
D1RCre 
matched the molecular 
signature of human HD considerably better than the R6/2 mice.  
 Taken together these studies suggest nucleolar stress is a mediator of 
neurodegeneration in HD.  While several neurodegenerative diseases contain evidence 
for insufficient ribosomal biogenesis, HD appears to contain several mechanisms capable 
of inhibiting RNA Polymerase I and inducing  p53-mediated apoptosis.  Moreover, both 
htt derived protein and RNA have been linked to toxicity.  Therefore, nucleolar stress 
appears to be a major contributor to HD-associated neurodegeneration. 
C9ORF72 Hexanucleotide repeat expansion - Amyotrophic Lateral Sclerosis (ALS) 
and Frontotemporal Dementia (FTD) 
 Hexanucleotide repeat expansions in the C9ORF72 gene (C9) have been causally 
linked to both ALS and FTD, however the mechanisms are still under debate.  C9ORF72 
expansion is the most common source of both familial Amyotrophic Lateral Sclerosis 
(ALS) and Frontotemporal Dementia (FTD).  In the literature estimates for the 
percentage of ALS/FTD caused by C9 hexanucleotide expansion have been highly 
variable (20%-67%).  The ALS association reports it accounts for approximately 40% of 
familial cases.  Regarding familial FTD, C9 is believed to account for approximately 
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25% of cases.  Interestingly, in very rare circumstances C9ORF72 expansion has also 
been linked to Parkinsonism [138]. 
 Three major hypotheses exist regarding C9ORF72 pathology; 1.-protein based 
gain of function, 2.-RNA based gain of function, and 3.- loss of function of the C9ORF72 
gene.  It is important to note that these theories are not mutually exclusive, multiple 
mechanisms are possible, and evidence supporting all three can be found in the literature.  
However, there are no loss of function studies implicating nucleolar involvement.  
Contained within these 3 theories are 7 potentially toxic species, 5 dipeptide repeats 
(DPRs) and 2 long repetitive RNAs, both sense and anti-sense [252].  Long non-coding 
RNAs derived from highly repetitive sequences are believed to be translated by repeat 
associated non-ATG (RAN) translation [268].  The mechanisms of RAN translation are 
poorly understood, but the process is believed to be different from canonical AUG 
initiated CAP -dependent and -independent translation.  As RAN translation can occur in 
either the sense or anti-sense direction and all reading frames are potentially possible, 5 
different DPRs could theoretically arise from GGGGCC hexanucleotide repeats, poly-
proline-arginine (PR), poly-glycine-arginine (GR), poly-glycine-alanine (GA), poly-
glycine-proline (GP), and poly-proline-alanine (PA) [252].  Importantly, all 5 DPRs have 
been detected in post mortem ALS and FTD tissues. 
 Recent cell culture based studies suggest that the two arginine rich DPRs, poly-
GR and poly-PR, are the major toxic species [129, 175, 240, 252].  Moreover, intricate in 
vitro studies have demonstrated that these two DPRs have a clear length dependence and 
dose response, as increasing plasmid dosage increased toxicity [252].  Multiple 
laboratories have suggested that these two peptides have a strong affinity for the 
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nucleolus, a feature which is not seen with the other three species.  Tao et.al. (2015) 
showed that expression of poly-GR and poly-PR can produce significant reductions in 
18S and 28S rRNA in just 48 hours [240].  Wen et.al. (2014) demonstrated that nucleolar 
aggregation preceded cell death [252].  In all cases neuronal death occurred 24 to 72 
hours after arginine rich DPRs aggregated in the nucleolus and interestingly, cells with 
DPRs which remained diffuse did not die during the course of their study.  However, it is 
important to note that some studies were not able to detect poly-GR in the nucleolus and 
DPR localization is not always consistent when comparing cell culture studies to post 
mortem tissue [219, 259].  Interestingly, one study, which did not report nucleolar 
localization of poly-GR, still documented nucleolar enlargement.  Impairment of RNA 
processing bodies and altered RNA stress granule formation has also been reported after 
overexpression of poly-PR and/or poly-GR[252]. 
 Kwon et al. (2014) has proposed that the two arginine containing dipeptide 
repeats essentially mimic the low complexity serine arginine (SR) domains which are 
contained in many pre-mRNA splicing factors such as, serine-arginine splicing factor 2 
(SRSF2) [129].  Poly-SR, poly-GR, and poly-PR were all shown to bind heterogeneous 
nuclear ribonucleoprotein A2 (hnRNPA2) hydrogels, structures which display a high 
affinity for RNA granule components.  However, SR domain proteins release binding 
following phosphorylation, a feature which cannot occur on the serine deficient poly-PR 
and poly-GR dipeptide repeats.  They demonstrated that both 47S pre-rRNA and mRNAs 
had impairment of processing and aberrant splicing following treatment with recombinant 
DPRs.  Similar findings have also been documented in human samples as the frequency 
of splicing errors is significantly higher in C9ORF72 patients compared to healthy 
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controls [37].  Interestingly, the frequency of errors correlates well with disease severity 
[37].  Such a phenotype could be potentially explained by arginine rich DPRs irreversibly 
binding RNAs and out competing mRNA splicing factors and pre-rRNA processing 
machinery.  In support of this concept, PR and GR dipeptides localized to both nucleoli 
and nuclear puncta, which have been proposed to be sites of pre-mRNA splicing [252].  
 While several studies have demonstrated that C9ORF72 RNA species are toxic, 
only one has been linked to the nucleolus [79, 102, 252].  Haeusler et.al. (2014) proposed 
that the hexanucleotide repeat region of C9ORF72 forms both G-quadruplex structures 
and DNA-RNA hybrids which impede and ultimately stall RNA polymerase I generating 
“abortive transcripts” [79].  They demonstrated that these abortive transcripts had a 
significant affinity for both nucleolin, a fundamental nucleolar protein necessary for pre-
rRNA processing, and the ribosome itself.  Hexanucleotide repeat RNA transcripts 
localized to the nucleolus and in turn altered its morphology.  Nucleoli were abnormally 
large and had a fragmented shape.  Such morphology is not indicative of canonical 
nucleolar stress, but may suggest some degree of functional impairment. 
 Several studies, both DPR and RNA based, have described abnormally large 
fragmented nucleoli [79, 240, 252].  The size of the nucleolus is believed to be related to 
the amount of pre-rRNA stored within its borders, thus such a finding suggests two 
possible conditions.  First, increased nucleolar activity could potentially be a 
compensatory response.  Alternatively, decreased pre-rRNA processing could increase 
retention and allow for accumulation.  The latter possibility appears most likely because, 
as previously mentioned; impairment of pre-rRNA processing has been detected after 
pharmacological treatment with recombinant poly-PR [129].  Importantly, while such a 
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condition is not indicative of canonical nucleolar stress, it may still represent impairment 
of ribosomal biogenesis.  Nishimura et.al. (2015) showed that impairment of pre-rRNA 
processing can produce enlargement of the nucleolus and induce p53 through ribosomal 
proteins/MDM2 interactions [187].  Theoretically, inhibition of RNA Polymerase I and 
impairment of pre-rRNA processing should both produce stoichiometric errors in 
ribosomal components. 
 In conclusion, numerous studies depicting nucleolar involvement in response to 
C9 toxicity have been reported.  However, none of these studies have unequivocally 
demonstrated the induction of nucleolar- or ribosomal stress.  Therefore, the role of the 
nucleolus in C9 linked ALS and FTD appears to a promising topic for future studies. 
Alzheimer’s Disease 
 While nucleolar stress has not been directly implicated in Alzheimer’s disease 
(AD), several studies have documented abnormalities in nucleolar volume and reduced 
ribosome content in Alzheimer’s disease brain tissue.  Over 30 years ago, Langstrom et 
al. (1998) initially documented decreased ribosome content in the frontal lobe of AD 
patients [132].  Moreover, the translation capacity per ribosome was also decreased.  
Importantly, such deficits were not seen in cerebellar tissues suggesting that impairments 
were specific to areas undergoing AD pathology.  More recently, AD associated proteins 
synthesis deficits were confirmed by Ding et.al. (2005) using ribosomes purified from the 
inferior parietal lobe and superior middle temporal gyri [48]. 
 Interestingly, there are conflicting reports about total ribosome content in AD.  
The aforementioned study by Ding et.al. (2005) concluded that total ribosome content 
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was unchanged in AD and MCI [48].  The authors were unable to identify decreases in 
ribosomal proteins or the 18S and 28S rRNA in patient tissues.  However, they did report 
decreases in the 5S and 5.8S rRNAs.  Ultimately, they concluded that total ribosome 
content was unchanged between AD and controls based on the constancy of the major 
RNA species and ribosomal proteins.  Additionally, they documented significant 
increases in rRNA oxidization in both Alzheimer’s disease and Mild Cognitive 
impairment.  Such a condition could potentially explain the protein synthesis deficits seen 
in AD.  They proposed that ribosomes were undergoing qualitative, rather than 
quantitative deficits.  To paraphrase, they hypothesized that in regions of the brain which 
experience AD-associated pathology the pool of ribosomes was damaged and operating 
at suboptimal levels. 
 A year later this same group applied different methods for quantifying ribosomal 
content and found significant decreases in both the 18S and 28S rRNAs [47].  The Initial 
study utilized qPCR to measure total ribosome content, while the follow up study utilized 
spectrophotometric measurements after serial fractionation.  Importantly, these deficits 
were found in both the mature 80S ribosomes fraction and precursor fractions.  
Interestingly, a recent report from the Ferrer laboratory was able to confirm decreased 
28S rRNA in the CA1 region of the hippocampus in all stages of AD, but surprisingly 
18S rRNA was unchanged [89].  They also reported decreases in some, but not all, 
ribosomal proteins.  As ribosomes are large multicomponent complexes such 
stoichiometric imbalances suggest decreased ribosome content, despite the constancy of 
some components.  In support of this concept, two groups have documented decreased 
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nissl staining intensity in both AD hippocampal neurons compared to controls [89, 150].  
Nissl staining intensity is frequently used as a marker of cellular ribosome content [226]. 
 Several reports also suggest impairment of RNA polymerase I.  First, increased 
rDNA promoter methylation was demonstrated in both MCI and AD brain tissues [206].  
Promoter methylation is used as a biomarker for recent transcriptional activity.  
Additionally, two very similar studies conducted almost a decade apart both identified 
decreased silver staining in the lymphocytes of AD patients [50, 200].  Such a phenotype 
is characteristic of decreased rRNA synthesis.  Moreover, expression of the RNA Pol I 
cofactor Upstream binding factor and nucleophosmin 1 were significantly decreased in 
early AD [89].  Taken together these findings strongly suggest neuronal ribosome content 
is indeed decreased in AD. 
 Regardless, qualitative and quantitative deficits both suggest a failure of 
ribosomal biogenesis in AD.  Homeostatic mechanisms would be expected to replace 
ribosomes which have incurred considerable amounts of oxidative damage.  As ribosomal 
biogenesis is a highly dynamic processes which is known to be intricately regulated by 
numerous processes, both acute and chronic, it would be highly unexpected if cells did 
not up regulate ribosomal biogenesis in response to deficits in protein synthesis capacity.  
Therefore, both outcomes suggest a failure of homeostasis.  In support of this concept, 
hypertrophic nucleoli have been identified in asymptomatic AD [95].  However, once 
patients became symptomatic (i.e. mild cognitive impairment and AD) nucleolar volume 
was significantly decreased [95].  Such findings suggest that neurons may indeed 
undergo an early homeostatic up regulation of ribosomal biogenesis, which subsequently 
fails in the later stages of AD. 
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 It is important to consider that evidence for an AD-associated decrease in RNA 
pol I activity was derived from brain tissue, neurons, and peripheral lymphocytes.  
Numerous studies have documented decreased metabolic activity and hypoperfusion in 
the AD brain [22, 144].  As RNA Pol I is tightly regulated in response to metabolic 
stimuli, one could argue that such a phenotype occurs near the end of the disease cascade 
and is simply the result of hypoperfusion.  However, the finding that peripheral 
lymphocytes also display decreased RNA Pol I activity suggests otherwise.  Moreover, 
decreased UBF and NPM1 expression was shown to occur in the early stages of AD, well 
before neuronal death occurs [89].  As such, impairment of ribosomal biogenesis may 
indeed be an early feature of AD-associated neurodegeneration and not simply a 
downstream consequence of hypoperfusion or end-stage degeneration.  
Neurodegeneration-associated Expansion of the rDNA locus 
 It is well accepted that highly repetitive DNA sequences can be notoriously 
unstable and this feature is especially true for ribosomal DNA [67, 97, 117, 119].  In 
1972, Bernard Strehler proposed that neuronal rDNA loss was a feature of mammalian 
aging, although this hypothesis has subsequently been disproven [68, 69, 105, 205].  In 
some cases alterations in cellular rDNA content appear to be physiologically relevant 
responses the cell purposely undertakes.  For example, it is known that amphibian 
oocytes have significantly amplified quantities of rDNA and this amplification is not 
maintained into adulthood [21, 174].  While the exact purpose of this amplification is not 
known, it seems logical that this feature could facilitate the rapid cell growth and 
expansion necessary during the early stages of development.  Alternatively, loss of rDNA 
in yeast is believed to contribute to replicative senescence by triggering the DNA damage 
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response [118, 120].  The instability of rDNA is also evident in a number of pathologies 
including several forms of cancer, Bloom syndrome and ataxia telangiectasia [112, 234].  
Interestingly, Werner syndrome has been associated not with changes in rDNA content, 
but instead with inversion of rDNA repeats [28].  The pathophysiological relevance of 
rDNA rearrangements is not known. 
 These findings and the AD associated ribosome abnormalities detailed in the prior 
section prompted our group to investigate rDNA gene content and promoter methylation 
in Alzheimer’s disease and Dementia with Lewy Bodies.  One potential explanation for 
an inadequate supply of ribosomes could be decreased synthesis of pre-rRNA.  As stated 
previously, pre-rRNA synthesis is believed to be regulated in two ways first, by altering 
the number of actively transcribed copies and second, by altering the activity at each 
individual copy.  Thus, by measuring promoter methylation, which is a mechanism for 
epigenetic rDNA silencing and a biomarker of recent activity, one can determine if rDNA 
copies were silenced.  Moreover, loss of rDNA copies could also potentially explain 
ribosomal insufficiency.   
 In AD, rDNA promoter methylation was indeed increased, but unexpectedly 
rDNA content was also significantly increased [206].  In cell lines, increased rDNA 
promoter methylation was shown to resist rDNA instability[77].  The increased stability 
was demonstrated using cell lines transfected with shRNA directed against TTF 
interacting protein 5 (TIP5), which is a key component of the complex responsible for 
rDNA methylation.  The authors demonstrated a loss of rDNA content in shTIP5 cells 
after ten passages.  Such a mechanism raised an important question.  Was the AD-
associated increase in rDNA content the result of hyper methylation protecting against an 
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aging associated loss of rDNA or alternatively, was this feature a disease-associated 
amplification? 
 Despite the fact that Strehler’s theory of aging related rDNA loss appeared to be 
thoroughly debunked in the 1970s, our results raised serious questions [68, 69].  
Mechanistically, prevention of loss seemed more plausible than disease associated 
amplification.  Therefore we revisited Strehler’s hypotheses and probed rDNA content in 
both young and old tissue donors.  Additionally, we chose to probe Dementia with Lewy 
Bodies tissue donors to determine if our prior results were  specific to AD or if they were 
a general consequence of neurodegeneration.  We found that there was no difference in 
rDNA content between young (2-25) and old (73-90) individuals as determined by qRT-
PCR using two separate rDNA amplicons [81].  Additionally, we found that similar to 
AD, rDNA content was increased in the cortex of DLB patients [81].  However, that is 
where the similarities ended.  rDNA methylation was unchanged in DLB and rDNA 
content was unexpectedly decreased in the pathology free cerebellum [81].  Such findings 
suggest that our prior AD results were not the prevention of rDNA loss and that DLB and 
AD may represent two separate phenomena. 
Chemotherapy-associated neurological conditions 
 While not being neurodegenerative diseases per se, two neurological conditions, 
Chemotherapy-associated cognitive dysfunction and Chemotherapy induced peripheral 
neuropathy (CIPN) have the potential to involve nucleolar dysfunction.  Relative to other 
diseases, very little is known about these two conditions.  While CIPN is a well-
documented phenomenon, it has historically been an afterthought for the research 
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community.  Early cancer research focused heavily on effectiveness.  Side effects were 
simply not a priority [54].  However, as success rates for chemotherapeutic treatment 
have increased dramatically over the last two decades, interest in CIPN and 
Chemotherapy associated cognitive dysfunction are now growing rapidly [26, 54, 190].  
Additionally, the concept of Chemotherapy-associated cognitive dysfunction, or 
“chemobrain” as survivors refer to it, is only just beginning to be an accepted medical 
condition [190].  To date, direct evidence for nucleolar stress in either of these conditions 
has not appeared in the literature.  In this section I will provide a general overview of 
both chemobrain and CIPN and summarize the evidence depicting nucleolar stress in 
response to many common chemotherapeutics.  Lastly, I will present a working model in 
which nucleolar stress may indeed be a major source of chemotherapy associated 
neuronal dysfunction. 
 “Chemobrain” is a condition of cognitive impairment which is associated with 
chemotherapeutic cancer treatment.  Patients commonly described it as a mental “fog” 
[190].  To date, very little is known about the source of chemobrain as it is only 
beginning to be accepted as a legitimate neurological condition.  Additionally, some have 
proposed that this condition is not simply a side effect of certain chemotherapeutic drugs.  
In addition to pharmacological toxicity, stresses related to hormone therapy, surgery with 
general anesthesia, and radiation treatment have all been proposed to play a role in 
chemobrain [172]. 
 Two decades ago chemobrain was a highly controversial topic and evidence for 
its existence was mostly anecdotal.  More recently, numerous studies have validated its 
existence in patients who are actively undergoing chemotherapy [190].  However, the 
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severity and frequency of chemobrain varies wildly depending on the study.  For 
example, moderate to severe cognitive deficits have been reported to occur in anywhere 
from 18% to 78% of breast cancer patients [103].  For perspective, 8% of the general 
population report having cognitive deficits [179].  Moreover, many patients present with 
fairly heterogeneous symptoms, however most display deficiencies in learning new 
information and accelerated forgetting of information [218].  While acute chemobrain is 
now well accepted, chronic forms are still debatable [190, 221].  Numerous studies both 
for and against the concept of a chronic post-treatment chemobrain have been reported.  
Such differences in findings may be due to factors such as individual heterogeneity, 
differences in choice of chemotherapeutic and differences in the duration of treatment 
[179]. 
 It is important to consider that the mechanism of action for many 
chemotherapeutics is still fairly ambiguous.  Moreover, many drugs may also be multi-
mechanistic.  A classic example of this phenomenon is 5-fluorouracil (5-FU).  For years 
it was believed that 5-FU’s primary mechanism of action was DNA damage [148, 197].  
While 5-FU does indeed damage DNA by depleting the cell of dTTP and inducing the 
incorporation of dUTP into DNA, it also inhibits processing of pre-rRNA and mRNA 
splicing [237, 265].  Recent reports suggest the latter effect may actually be the major 
driver of 5-FU toxicity.  Sun et.al. demonstrated that 5-FU impaired ribosomal biogenesis 
and induced p53 in RPL5 and RPL11 dependent manner [237].  Moreover, administration 
of thymidine which replenishes cellular pools of dTTP, thus preventing dUTP 
incorporation, produced only a minor rescue of cell survival following 5-FU treatment 
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[209].  Such results suggest that DNA damage is only a minor component of 5-FU 
toxicity. 
 Some have speculated that the nucleolus is the master regulator of the p53 
response [23].  With regard to the DNA Damage response, Rubbi and Milner showed via 
highly focused UV radiation that nucleolar function must be altered before p53 would 
accumulate [217].  Severe DNA damage outside the nucleolus was unable to induce p53.  
It appears that cells are essentially sampling ribosomal DNA to approximate genome 
wide DNA damage.  Moreover, it has been shown that p53 levels fluctuate inversely in 
response to relatively minor changes in the rate of ribosomal biogenesis, such as in 
response to cellular energy levels [126].  Thus, the nucleolus may indeed be a master 
regulator of p53. 
 Given the ambiguity detailed above and the emerging evidence suggesting the 
nucleolus as a master p53 regular, Burger et al. tested 36 common chemotherapeutics for 
an effect on ribosomal biogenesis [23].  The chosen drugs originated from 9 different 
classes.  They showed that 16 common chemotherapeutics had large effects on either pre-
rRNA synthesis, pre-rRNA processing, or induced the dispersion of NPM.  Four others 
had modest effects.  Sixteen drugs had no effect on ribosomal biogenesis or nucleolar 
morphology.  Interestingly, while some classes of drugs produced similar effects, this 
was not always the case.  For example, all intercalating agents tested (4/4) potently 
inhibited RNA pol I, whereas none of the HDAC inhibitors (0/2) or mitosis inhibitors 
(0/2) produced potent effects.  However, one mitosis inhibitor, Paclitaxel, did manage to 
produce some effect on late pre-rRNA processing.  Conversely, alkylating agents were 
highly heterogeneous.  Cisplatin and Oxaliplatin both strongly inhibited pre-rRNA 
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synthesis, while 6 others in this class had no effect and one had a weak effect.  Similarly, 
antimetabolics were also highly heterogeneous, with 5-fluorouracil and methotrexate 
producing potent effects, while 5 others did not. 
 In contrast to chemobrain, chemotheraphy-induced peripheral nucleopathy is 
considerably better characterized.  CIPN has a rate of incidence of approximately 30-40% 
and is typically a sensory neuron specific condition [257].  However, motor and 
autonomic functions have been reported to occur at very high doses [51, 61, 143, 254].  
Symptoms typically include burning, tingling, hyper sensitive touch and cold sensation, 
loss of proprioception, loss of perception of vibration, loss of pinprick, and numbness 
[54].  Symptoms begin in a stocking and glove pattern [196].  This suggests that the 
largest neurons are preferentially susceptible and many speculate this condition is 
primarily an axonopathy [54].  While CIPN is not a critical condition, the patient’s 
quality of life is often dramatically impacted.  The time required for symptoms to resolve 
varies greatly and is believed to depend on the class of drug, duration of treatment, and 
total cumulative dose [34, 54].  Generally, most cases of CIPN resolve approximately 3-6 
months following cessation of treatment [8].  However, in some cases it has been 
reported that CIPN can take up to 9-13 years to resolve [180, 232]. 
 Four classes of chemotherapeutics are most frequently associated with CIPN.  
These classes include platinum containing agents, proteasome inhibitors, microtubule 
targeting agents, and angiogenesis inhibitors.  Interestingly, the one chemotherapeutic 
agent most commonly associated with CIPN, oxaloplatin, is known to have a robust 
effect on nucleolar function.  86% of patients receiving oxaliplatin report immediate 
symptoms [7, 256].  Oxaloplatin is known to decrease nucleolar size in the dorsal root 
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ganglion of adult rats given pharmacologically relevant doses [99].  Moreover, in cell 
culture models oxaloplatin robustly inhibits rRNA transcription, disperses 
nucleophosmin, and induces fibrillarin nucleolar caps [23].  In general, inhibition of 
rRNA polymerase I appear to be a common feature of platinum containing alkylating 
agents [70, 167].  Interestingly, cisplatin, another platinum containing alkylating agent, is 
associated with a delayed onset form of CIPN which peaks after cessation of treatment 
[19]. 
 Several studies suggest that proteasome inhibitors, such as Bortezomib, affect 
nucleolar function.  Similar to oxaloplatin, peripheral neuropathy is the number one dose 
limiting side effect of bortezomib treatment [192].  Bortezomib’s primary mechanism of 
action is the reversible inhibition of the chymotrypsin like activity of the β5 proteasome 
subunit [2].  Downstream effects are known to include endoplasmic reticulum stress, up 
regulation of pro-apoptotic factors, and inhibition of NF-κB [165].  Interestingly, upon 
proteasome failure multiple proteasome targeted proteins have been shown to accumulate 
in the nucleolus [133].  Similarly, PML-containing nuclear bodies also translocate to the 
nucleolus under such conditions [192]. 
 A recent report from the Lafarga laboratory documented increased nucleolar 
volume, increased number of nucleoli, enhanced cajal body assembly, and increased pre-
rRNA synthesis in sensory ganglion neurons following bortezomib treatment [192].  
They proposed that increased nucleolar activity was potentially a homeostatic mechanism 
to protect the neuron in response to proteotoxic stress.  In support of this concept, 
expression of the transcription factor c-Myc was increased while p53 was decreased.  
Such findings strongly suggest this may indeed be a protective response.  Moreover, the 
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authors thoroughly demonstrate a lack of RNA polymerase I inhibition.  However, it is 
important to consider other potential mechanisms and outcomes in response to the 
hypertrophic nucleoli. 
 In contrast to the findings detailed above, Burger et al. has documented that both 
Bortezomib and MG-132 inhibit late pre-rRNA processing [23].  In cycling cells, such a 
condition is sufficient to produce hyper trophic nucleoli and induce the ribosomal stress 
response [187].  In addition to processing impairments, ribosomal stress associated 
hypertrophic nucleoli can also be triggered by oncogenic stimuli [187].  Such a condition 
could potentially follow significant increases in c-myc expression which interestingly 
was described by the Lafarga group.  Therefore, more work is necessary to truly 
determine if bortezomib induced hyper trophic nucleoli are indeed a homeostatic 
response or alternatively, a biomarker of nucleolar stress. 
 Similar to bortezomib, the microtubule targeting agent Paclitaxel is also 
associated with both hyper trophic nucleoli and peripheral neuropathy [99, 100].  
Interestingly, co-administration of paclitaxel with oxaloplatin prevents oxaloplatin 
induced reduction in nucleolar size.  This phenotype was also associated with reduced 
neurotoxicity.  Such a condition is perplexing.  Oxaloplatin is a well-documented inducer 
of DNA damage and its ability to inhibit RNA polymerase I is most likely due to this 
feature.  Increased DNA repair would be required for restoration of RNA Pol I activity 
under such conditions.  It is unlikely that a cytotoxic agent such as paclitaxel would 
induce accelerated DNA repair.  The more plausible hypothesis is that paclitaxel inhibits 
pre-rRNA processing similar to several other chemotherapeutics, such as 5-FU, 
bortezomib, and MG-132 [23].  However, to the best of my knowledge this has not been 
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reported in the literature.  It will be important for future studies to address if inhibition of 
pre-rRNA processing is a common mechanism for inducing CIPN. 
 As detailed previously, I propose that ongoing ribosomal biogenesis is necessary 
for neuronal growth, maintenance, and repair.  Given the well documented involvement 
of nucleolar stress in response to many common chemotherapeutics, I hypothesize that 
these agents induce a failure of neuronal maintenance.  Under such conditions, chronic 
administration of chemotherapeutics would induce a gradual neuronal atrophy, ultimately 
leading to synapse loss and potentially a minor decrease in axonal length.  Upon removal 
of chemotherapeutics normal function would be restored.  Subsequently, symptoms 
would resolve following a period of regrowth and the generation of new synapses.  
Interestingly, the kinetics of such a model match well with the regenerative capacity of 
each class of neurons, as CIPN resolves faster than chemobrain in most cases.  In support 
of this concept, CIPN is known to begin in a stocking and glove pattern [196].  Such a 
phenotype strongly suggests that the largest neurons are the most vulnerable [54].  
Coincidently, neuronal size strongly correlates with nucleolar size [130].  Robust 
nucleolar output is believed to be necessary to maintain such large sizes [91].  Thus, one 
would expect larger neurons to be disproportionately affected by a nucleolar loss of 
function. 
 In summary, the nucleolus is an integral component of neuronal function and its 
role is significantly larger than just ribosome production.  The studies reviewed in this 
chapter clearly demonstrate several key points.  First, ongoing ribosomal biogenesis is 
necessary for the growth of young neurons and maintenance of mature neurons.  Second, 
the nucleolus contains free ribosomal protein that may activate stress response pathways 
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providing a mechanism to monitor the fidelity and effectiveness of ribosomal biogenesis.  
Third, there is ample evidence for nucleolar dysfunction in many neurodegenerative 
diseases.  Moreover, in the case of poly glutamine diseases there is considerable evidence 
suggesting the engagement of the nucleolar stress response.  However, it remains to be 
seen if the nucleolar and ribosomal stress mechanisms predominately described in yeast, 
cell lines and mouse liver are applicable to the mammalian nervous system.  Therefore, 
we propose to investigate the role of the nucleolus, and specifically RPL11 in 




NEURODEGENERATION ASSOCIATED INSTABILITY OF RIBOSOMAL DNA 
Introduction 
 The age-related accumulation of DNA damage, and the subsequent genomic 
instability which follows, has been proposed as a mechanism for proliferative senescence, 
cancer, and neurodegeneration, all of which are associated with aging or aging-related 
disorders [109, 117, 147].  DNA damage is well documented in neurodegeneration and in 
some cases it may be sufficient to cause disease [92, 109].  Moreover, significant 
increases in oxidative DNA damage are known to occur in PDAD, PD, and DLB [151, 
158].  Additionally, multiple congenital diseases involving mutations of DNA repair 
proteins often involve neurodegeneration.  These diseases include ataxia with oculomotor 
apraxia 1, spinocerebellar ataxia with axonal neuropathy 1 and xeroderma pigmentosum 
[20, 30, 92, 109, 211].  Moreover, DNA damage is well known to induce cell death by a 
number of mechanisms including inhibition of nucleolar transcription and genomic 
instability [92, 106].   
 Homologous recombination is believed to be the preferred DNA damage repair 
mechanism as it produces the highest fidelity, while other repair mechanisms such as 
non-homologous end joining are known to frequently generate single nucleotide 
polymorphism [181].  Homologous recombination utilizes homologous templates, usually 
a sister chromatid, to repair DNA double strand breaks, inter-strand crosslinks, and 
stalled replication forks.  The major limitation is that sister chromatids are only available 
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during the late S and G2 phases of the cell cycle [181].  Interestingly in yeast, the 
mechanisms for increasing ribosomal DNA content have been proposed to be 
homologous recombination with unequal sister chromatid exchange [119]. 
 Homologous recombination may potentially act as a double-edged sword in 
regards to genomic stability.  Efficient and accurate DNA repair allows the cells to resist 
replication stress and maintain genomic stability, thus preventing oncogenic 
transformation [140].  Conversely, a growing body of evidence suggests that homologous 
recombination can be a source of genomic instability in response to regulatory failure 
[31, 123, 222].  For example, it has been suggested that the Rec Q helicases BLM and 
WRN, whose mutations are linked to Bloom Syndrome and Werner Syndrome 
respectively, act as negative regulators of homologous recombination [12].  Additionally, 
in Werner syndrome, Bloom syndrome, and several subsets of Rothmund-Thomson 
syndrome, which is a third Rec Q linked disease, individuals have a predisposition for 
cancer [35].  Moreover in yeast, mutation of the slow growth suppressor 1(SGS1) 
helicase creates a hyper recombination phenotype which is associated with frequent 
segmental deletions.  Overexpression of the WRN or BLM Rec Q helicases can produce 
a partial rescue from this hyper recombination. [258].  Thus, while homologous 
recombination is of great importance due to its high fidelity DNA repair capabilities, tight 
regulation is necessary to prevent promiscuous potentially oncogenic recombination. 
 Recent evidence suggests the dysregulation of homologous recombination in 
neurodegenerative diseases.  The gradual loss of telomeres is a well-documented aspect 
of cellular senescence, but interestingly both expansions and contractions of telomere 
content have been documented in neurodegenerative disease.  Accelerated telomere loss 
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has been documented in the leukocytes of patients with AD and DLB [29, 127, 216, 243].  
Conversely, increased telomere content has been documented in the hippocampus of AD 
patients [243].  Moreover, Pietrzak et al. (2011) have previously an increase in the 
ribosomal DNA content of parietal- and prefrontal- cortex of AD donor tissues [206].  
Changes in the genomic content of highly repetitive sequences, especially those which 
occur in terminally differentiated cells which do not express telomerase, strongly suggest 
homologous recombination as a potential mechanism. 
 The tandem repeat arrangement of ribosomal DNA is well known for its relative 
instability compared to other regions of the genome [112, 118, 234].  The combination of 
this arrangement and the close physical proximity of all ten arrays inside the nucleolus 
potentially make them hot spots for homologous recombination.  Uneven homologous 
recombination between clusters or within a cluster may lead to expansions or contractions 
of ribosomal DNA content and such a process is common in yeast [119].  In 1972, 
Bernard Strehler proposed the loss of ribosomal DNA copies in post-mitotic cells, such as 
neurons and muscle, as a mechanism of senescence [105].  Strehler proposed that this 
loss would subsequently lead to a deficiency in the ribosomal supply and insufficient 
levels of protein translation.  While his initial results were promising, they were later 
refuted as experimental artifact as subsequent studies could not reproduce these 
observations [68, 205].   Moreover, mammalian cell culture based studies of replicative 
senescence did not document changes in ribosomal DNA content [80, 152]. 
 Cellular growth and maintenance require enormous amounts of protein synthesis.  
The ribosome is the center of all cellular translation and as such ribosomal quantities are 
linked to the cell’s protein synthesis capacity [76].  To accommodate the demand for 
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increased protein synthesis, cells have amplified the ribosomal DNA gene which encodes 
for pre-rRNA, a transcript which is processed into the 18S, 5.8S, and 28S ribosomal 
RNAs (rRNAs).  In eukaryotes, ribosomal DNA content is believed to range from 100-
10,000 copies depending on the species [76].  Humans are estimated to have 
approximately 300 copies per haploid genome, which are organized in clusters of long 
tandem arrays on chromosomes 13, 14, 15, 21 and 22 [234].  Interestingly, in mature cells 
only about half of the ribosomal DNA copies are transcriptionally active while the other 
half is epigenetically silenced [169].  This excess number of rDNA copies suggests two 
possibilities.  First, the cellular demand for protein synthesis may vary greatly throughout 
a lifespan.   For example, such a large number of copies may be essential for rapid 
proliferative growth and early development, but unnecessary upon maturity.  
Alternatively, excess ribosomal DNA copies may function to allow cells to tolerate the 
loss of damaged copies.  Such a condition may be of great importance for post-mitotic 
neurons which survive for an organism’s entire life span.  Moreover, these excess 
ribosomal DNA copies have evolved to have functions unrelated to ribosomal biogenesis, 
such as regulating chromatin structure, gene expression, and stress response [10, 77, 97, 
193, 195]. 
 Alternatively, in yeast the age related loss of ribosomal DNA is known to occur 
and has been proposed as the mechanism behind replicative senescence.  Originally, it 
was thought that ribosomal DNA instability lead to the production of extra chromosomal 
circles (ERCs) a ribosomal DNA cleavage product composed of 8 ribosomal DNA units 
[110].  It was proposed that these ERCs would titrate out the factors necessary for 
ribosomal biogenesis and genome maintenance.  However, more recent work suggests 
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that ERCs are simply a marker of ribosomal DNA instability and that the loss of 
ribosomal DNA itself triggers the DNA damage response [67, 97].  Kobayashi has 
proposed that ribosomal DNA may act as a sink for DNA damage proteins, and thus 
release them in response to ribosomal DNA copy loss [117].  He went on to propose that 
such a function could monitor genomic integrity in a manner somewhat analogous to 
telomeres [117]. 
 Previously Pietrzak et al. (2011) has documented an increase in ribosomal DNA 
copy number in the parietal cortex tissue of AD positive tissue donors using a qPCR 
based approach [206].  Moreover, the increased copy number was associated with an 
increase in ribosomal DNA promoter methylation, which is a marker of inactive copies.  
Interestingly in a murine cell line, decreased epigenetic silencing correlated with loss of 
ribosomal DNA content [77].  These results sugguest to two mutually exclusive 
possibilities.  First, increased ribosomal DNA content could be the result of disease-
associated amplification or second, the increased methylation could be preventing an age-
associated loss of ribosomal DNA.  The latter possibility would suggest that the 
ribosomal DNA stability studies conducted in the 1970s and 1980s which disproved 
Strehler’s hypothesis of age related ribosomal DNA loss may have been inaccurate. 
 Despite the negative data generated several decades ago, it should be noted that 
the experimental design of these studies utilized a hybridization based competitive 
binding assay and as such did not allow for a high resolution picture of the ribosomal 
DNA genes.  The human ribosomal DNA gene is fairly large with a length of 43kb, of 
which roughly three fourths is the untranscribed intergenic spacer.  The other one fourth 
is composed of the promoter and 3 exons which include the 18S, 5.8S, and 28S rRNAs 
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(Fig.4).  The results created by the prior hybridization based approaches do not 
necessarily exclude segmental losses inside the ribosomal DNA unit.  In support of  
segmental ribosomal DNA loss a more recent study which used a quantitative PCR 
(qPCR)-based approach documented a modest, but still statistically significant, age 
related decrease in 5.8S and 28S ribosomal DNA content, but not 18S [263].  Moreover, 
a study which utilized in situ hybridization with fluorescent probes for 18S and 28S 
unexpectedly demonstrated that in healthy controls approximately one third of ribosomal 
DNA copies are arranged in a head-to-head or tail-to-tail orientation and not strictly in 
tandem arrays as the canonical model suggests [28].  Additionally, they found significant 
heterogeneity in the length of the intergenic spacer.  In fibroblasts obtained from Werner 
patients the frequency of this non-canonical arrangement increased to approximately 50% 
of total ribosomal DNA copies [28].  As Werner syndrome is known to be caused by a 
Req Q helicase mutation, this feature suggests homologous recombination is potentially 
involved in these abnormal rearrangements.  Thus, higher resolution techniques have 
suggested that segmental or directional variation of ribosomal DNA units may not be 
uncommon. 
 Independent of age-related ribosomal DNA changes, multiple studies suggest that 
ribosomal DNA is relatively unstable compared to other regions of the genome as its 
tandem repeat arrangement potentially makes them hot spots for homologous 
recombination mediated fluctuations in both yeast and higher organisms, including 
humans.  Meiotic ribosomal DNA recombination rates are believed to be as high as 10% 
and this subsequently causes significant heterogeneity in ribosomal DNA content even 
among closely related individuals [233].  In human cells, mitotic ribosomal DNA 
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instability is common in both cancer and congenital diseases linked to impaired DNA 
damage repair.  For example, in human cancers approximately 50% of lung and 
colorectal solid tumors demonstrate ribosomal DNA restructuring [234].  Moreover, this 
restructuring was also seen in fibroblasts from Ataxia Telangiectasia and Bloom 
syndromes, which are known to be caused by mutations in a DNA double strand break 
repair protein ATM and the BLM Rec Q helicase mentioned above [112, 234].  
Surprisingly, mutations in the Rec Q helicase WRN, which is implicated in Werner 
syndrome, did not alter the length of ribosomal DNA clusters [112].  Furthermore, as 
mentioned previously, the methylation status of the ribosomal DNA promoter and 
subsequent heterochromatin formation was directly linked to ribosomal DNA stability in 
a mammalian cell line [77].  Lastly, amphibian and insect oocytes amplify ribosomal 
DNA as extra chromosomal circles presumably to enable exceptionally high rates of 
rRNA synthesis necessary for early development [21, 141, 174].  Taken together these 
facts strongly suggest that ribosomal DNA content is unstable under both physiological 
and pathological circumstances in higher organisms. 
 Given the previously described increase in the 18S ribosomal DNA content in AD 
parietal cortex tissue and the increased ribosomal DNA promoter methylation which 
accompanied it, I investigated age related segmental changes in parietal cortex ribosomal 
DNA content.  Thus I acquired parietal cortex samples from 14 young and 9 elderly brain 
tissue donors, all of which were free of neurological and neurodegenerative conditions 
and probed all 3 ribosomal DNA exons.  Moreover, to determine if our prior findings are 
exclusively a characteristic of AD or alternatively a general correlate of 
neurodegeneration, parietal cortex samples from 10 DLB tissue donors and 10 healthy 
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age matched controls were probed in an identical manner.  Moreover, we acquired 
cerebellar tissue from DLB and control subjects to assess if the documented ribosomal 
DNA increases are confined to areas with pathology. 
 DLB is an age related neurodegenerative disease and is the second most common 
form of dementia in the elderly after AD.  The major symptom of DLB is memory loss, 
but fluctuations in alertness, Parkinsonian motor deficits, and visual hallucinations are 
also common [83].  Moreover, DLB is associated with the loss of dopaminergic neurons 
and frequently contains reactive gliosis [55, 220].  Pathologically, DLB is similar to PD 
as both are classified as synucleinopathies, diseases which are associated with 
intracellular inclusions of aggregated α-synuclein referred to as Lewy Bodies which 
develop in both neurons and glia [83].  Some have speculated that DLB and PD may be 
the same disease as they share significant symptomatic and pathological overlap.  For 
example, the major diagnostic difference between DLB and PD dementia for clinicians is 
only the rate of dementia onset.  DLB is associated with the widespread accumulation of 
Lewy Body pathology throughout the cortex, including the parietal- and prefrontal 
cortices which were probed in Pietrzak et al. (2011) [71, 206].  The cerebellum is 
predominately pathology free in DLB.  Thus, DLB should serve as an ideal specificity 
control for AD.  Moreover, synucleinopathies have been documented to contain increased 
amounts of oxidative stress and in particular increased amounts of oxidative DNA 




Methods and Materials 
Subjects and sample preparation. For aging studies fresh flash frozen samples of parietal 
cortex (Brodmann areas 39 and 40) were obtained from the NICHD Brain and the Tissue 
Bank for Developmental Disorders at the University of Maryland, Baltimore, MD.  The 
young donor group consisted of 7 men and 7 women (1-25 years old, median age: 20); 
the old donor group consisted of 4 men and 5 women (73-90 years old, median age: 79).  
The donors had no prior history of a chronic neurodegenerative- or neurological disease.  
The post mortem intervals were comparable for both groups averaging 7.5 h (Post 
mortem intervals were always less than 14 h).  For DLB studies, the donors were 
participants of the IRB-approved University of Kentucky AD Center cohort and were 
followed for at least 2 years before death [185].  The follow up included annual 
Minimental State Examination as well as neurological and physical examinations.  The 
donors had no history of substance abuse, head injury, encephalitis, meningitis, epilepsy, 
or stroke/transient ischemic attack.  The Minimental State Examination score closest to 
death was used as an indicator of overall cognitive status.  During autopsy (usually 5 or 
less hours after death), tissue samples including parietal cortex and cerebellum were 
processed for neuropathological evaluations or flash-frozen in liquid nitrogen and stored 
at -80°C, as described previously [1, 185].  All included DLB subjects met the clinical 
and histopathological criteria for diagnosis of DLB [186].  The control subjects received 
Minimental State Examination scores ≥ 23 with Braak staging at ≤ 2.  Detailed donor 




Analysis of genomic ribosomal DNA content.  Genomic qPCR using standard curve 
based analysis was utilized to determine ribosomal DNA content.  Amplicons targeting 
18S, 5.8S, and the 28S coding regions of ribosomal DNA were used (Fig.4).  For 
normalization, amplicons corresponding to the coding regions of the tRNA
K-CTT
 gene or 
the albumin gene (ALB) were amplified.  
 
Bisulfite mapping of ribosomal DNA promoter methylation was performed as described 
previously [206].  Briefly, two hundred ng of DNA/sample was treated with bisulfite to 
convert unmethylated cytosines to uracil.  The ribosomal DNA promoter region was 
PCR-amplified and cloned into the pGEM-T vector.  Following bacterial transformation, 
individual clones were isolated and sequenced.  Only clones with unique methylation 
patterns were included in the analysis to avoid potential PCR/cloning artifacts.  Clones 
with incomplete bisulfite conversion were also discarded.  Thus, twenty fully converted, 
and unique clones were analyzed for each individual.  
 
DNA methylation analysis using the methyl-CpG sensitive restriction enzyme HpaII. 
Methylation of the HpaII site located at position -9 relative to the transcription start site 
(CpG #23 of the human ribosomal DNA promoter) was analyzed with a quantitative real-
time PCR of the HpaII-digested genomic DNA as described previously [206] with 
modifications.  Importantly, as a reference, the HpaII-digested DNA was used as 
template to determine the content of an amplicon adjacent to the one with the HpaII site.  
Such normalization resulted in reproducible methylation values as opposed to using a 




Figure 4. The qPCR-based assay to determine the genomic content of ribosomal DNA 
The ribosomal DNA copies are organized as long tandem repeats located on five acrocentric chromosomes.  
Each copy consists of the ribosomal RNA gene and the intergenic spacer.  Each ribosomal RNA gene 
includes a Pol1-dependent promoter and exons that correspond to 18S-, 5.8S- and 28S ribosomal RNAs. 
They are separated by introns (5’ETS, ITS1, ITS2 and 3’ETS). The positions of the analyzed ribosomal 
DNA amplicons are indicated by the thick black lines. The schematics are not drawn in scale.  
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Evaluation of methylation effects on qPCR efficiency.  An unmethylated DNA template 
for the 5.8S amplicon was obtained by PCR on genomic DNA (primer sequences: 
forward cccgtggtgtgaaacctt, reverse agctagctgcgttcttcatc).  The PCR product was then in 
vitro methylated in a buffer containing 6 ng DNA/µL, 0.16 mM S-adenosylmethionine 
and 0.2 units M.SssI/µL (New England Biolabs) at 37°C for 2 hours followed by M.SssI 
inactivation at 65°C for 20 minutes.  Methylated and unmethylated templates were used 
for qPCR with the 5.8S amplicon primers.  To verify the extent of methylation, both 
methylated and unmethylated templates were incubated with the methyl sensitive 
restriction enzyme HpaII.  Template resistance to HpaII was determined by qPCR.  
 
Statistical analysis was performed using the non-parametric Kruskal-Wallis one way 
ANOVA and linear regression fitting.  In addition, comparisons of individual ribosomal 
DNA methylation sites were accomplished using a modified significance analysis of 
microarrays (SAM), as reported previously [206]. 
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Table 1. Young and old donors of the parietal cortex samples that were used for the 
aging studies. 











2 10 Male 
15 9 Female 
16 7 Male 
18 8 Female 
19 7 Female 
20 6 Male  
20 5 Male  
21 7 Male 
22 7 Male 
22 10 Female 
24 9 Female 
24 7 Female 
24 9 Male 
25 4 Female 





73 13 Female 
76 3 Male 
76 3 Female 
77 8 Female 
79 5 Male 
79 10 Male 
88 8 Female 
89 14 Male 
90 4 Female 
1
PMI, post mortem interval 
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Table 2. Control and Dementia with Lewy Bodies donors of the parietal cortex and 
the cerebellum samples that were used for the Dementia with Lewy Body studies. 
Group Age (years) PMI (h)
1
 Sex Parietal cortex Cerebellum 
Control 77 3.5 Male + Unavailable 
81 2 Male + Unavailable 
87 2.4 Male + Unavailable 
82 2.1 Male + Unavailable 
85 2.5 Female + + 
90 2 Female + + 
79 1.8 Female + + 
78 1.2 Male + + 
81 2.8 Male + + 
96 2.1 Female + + 
86 2.5 Female Not included + 
90 3.8 Female Not included + 
80 2.5 Female Not included + 
95 2.8 Female Not included + 
DLB
2
 78 2.5 Male + + 
78 3.8 Male + + 
81 2.5 Male + + 
72 2.8 Male + + 
65 9.5 Male + + 
87 2 Female + + 
68 3.8 Male + + 
90 2.5 Female + + 
82 2.3 Male + + 
91 10.5 Female + + 
1
PMI, post mortem interval, 
2
DLB, Dementia with Lewy Bodies 
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Table 3.  qPCR primers used for aging, Dementia with Lewy Bodies, and HPAII-
based methylation Studies. 
Primer Set Direction Sequence 5’ to 3’ 
18S Forward agcctgagaaacggctacca 
Reverse ggtcgggagtgggtaatttgc 
5.8S Forward gaggcaaccccctctcctctt 
Reverse gagccgagtgatccaccgcta 




 Forward ctagctcagtcggtagagcatg 
Reverse ccaacgtggggctcgaac 
ALB Forward cggcggcgggcggcgcgggctgggcggaaatgctgcacagaatccttg 
Reverse gcccggcccgccgcgcccgtcccgccggaaaagcatggtcgcctgtt 











Stability of the cerebro-cortical ribosomal DNA copy number in aging.  To assess the 
effects of aging on ribosomal DNA copy number in the brain, genomic DNA was isolated 
from post mortem parietal cortex samples that were collected from two groups of donors.  
The young donor group consisted of 14 individuals with a median age of 201.6 (range 
1-25, Table 1).  The old donor group included 9 individuals with a median age of 792.1 
(range 73-90, Table 1).  None of the donors were known to suffer from a chronic 
neurodegenerative and/or neurological disease.  The genomic content of 18S- and 28S 
rRNA coding regions of ribosomal DNA was analyzed by a qPCR assay (Fig.4).  For 
normalization, a coding region of the multi-copy gene tRNA
K-ctt
 was used.  There are 17 
almost identical copies of this gene in the haploid human genome.  However, in contrast 
to ribosomal DNA, they are not clustered together [33] and therefore, are less likely than 
ribosomal DNA to undergo recombination-associated instability.  
 As the investigated ribosomal DNA regions are physically linked, a direct 
correlation between their genomic content for each analyzed sample is expected (Fig. 4).  
Indeed, the individual values obtained for the 18S and the 28S amplicons were strongly 
correlated, fitting to a linear model of a direct correlation (Fig.5A, a=0.7327, R
2
=0.8103).  
These results support accuracy of the applied qPCR methodology for determination of the 
genomic ribosomal DNA content. 
 However, genomic content of 18S and 28S regions of ribosomal DNA did not 
significantly differ between the young- and the old subjects (Fig.5B, C).  Usage of a 




Figure 5. Effects of age on the cerebro-cortical content of ribosomal DNA 
Genomic ribosomal DNA content was quantified in post mortem samples of the parietal cortex from 
young- and old individuals without any neurodegenerative conditions (n=14, median age 20, and n=9, 
median age 79, respectively). The 18S- and 28S- amplicons were used for ribosomal DNA content 
determinations; the reference genes are indicated. For each amplicon, the ribosomal DNA content was 
normalized to average value of young individuals. A, Regression analysis of individual values of ribosomal 
DNA content as determined with 18S- or 28S probes. As expected for a close physical linkage between 
these genomic templates, a direct correlation is present supporting validity of the qPCR assay. Filled or 
opened diamonds indicate young or old individuals, respectively. B-D, Content of ribosomal DNA is 
similar in young- and old individuals. Individual values are depicted by squares; mean values are indicated 
by the lines intersecting the error bars (SEM); p values of the Kruskal-Wallis ANOVA are shown.
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similar results (Fig.5D).  Therefore, in the cerebral cortex, genomic content of ribosomal 
DNA appears to be stable throughout the lifespan.  
 
DLB-associated instability of brain ribosomal DNA.  To assess whether aging-related 
neurodegeneration affects genomic ribosomal DNA content in the brain, post mortem 
parietal cortex samples from ten patients who were diagnosed with DLB were analyzed 
(Table 2).  The control group included ten age-matched individuals who died of non-
neurological diseases and whose brains did not display any evidence of 
neurodegeneration (Table 2).  Similar to the midbrain-focused PD, DLB is a form of a 
synucleinopathy [168, 227].  Their common characteristic is the presence of 
intracytoplasmic α-synuclein-containing inclusions, the Lewy Bodies.  In addition, DLB 
is associated with neuronal atrophy, neuronal death and reactive gliosis in the cerebral 
cortex including the parietal region [168].  Oxidative damage of macromolecules 
including DNA is observed in both conditions [3, 151].  Hence, DLB and Parkinson’s 
disease may represent a similar pathological process that affects different areas of the 
brain.  
 Three ribosomal DNA coding regions were analyzed including probes 
corresponding to the 18S, 5.8S, and 28S exons (Fig.4).  As expected for a tight physical 
linkage, the DLB- and the control group-derived individual values obtained with these 
probes correlated with each other fitting a linear model of direct correlation (Fig. 
5A)(28S(18S), y=1.7416*x-0.6165, R
2
=0.8495; 5.8S(18S), y=1.4776*x-0.4126, 
R
2
=0.8957; 28S(5.8S), y=1.1008*x-0.0133, R
2
=0.8274).  Interestingly, genomic content 




Figure 6. Increased ribosomal DNA content in the Dementia with Lewy Bodies parietal cortex 
Genomic ribosomal DNA content was quantified in post mortem samples of the parietal cortex from DLB- 
and age-matched control individuals without any neurodegenerative conditions (n=10 each). The 18S-, 
5.8S- and 28S amplicons were used for the determinations; the reference genes are indicated. Regression 
analysis of individual values for pairs of ribosomal DNA amplicons revealed strong correlations similar to 
those in Fig.5A (see the Results section for more details).  In the DLB group, significant increases of 









(D) ratios. Individual values are depicted by squares; mean values are indicated by the lines 




Figure 7. Decreased ribosomal DNA content in the Dementia with Lewy Bodies cerebellum.   
Genomic ribosomal DNA content was quantified in post mortem samples of the cerebellum from 10 DLB- 
and 10 aged-matched control individuals. Regression analysis of individual values for pairs of ribosomal 
DNA amplicons revealed strong correlations similar to those in Fig. 5A (data not shown). While a 
downward trend was observed for the 18S amplicon (A), the 5.8S- and the 28S probes revealed significant 
decreases of ribosomal DNA content in DLB samples (B-C). Individual values are depicted by squares; 
mean values are indicated by the lines intersecting the error bars (SEM); p values of the Kruskal-Wallis 




 revealed ribosomal DNA content that was 1.6-, 2.0-, and 2.3-fold controls respectively 
(Kruskal-Wallis  ANOVA, p<0.01, Fig.6A-C).  Similar results were obtained when ALB 
was used as an alternative genomic reference (Fig.6D).  To determine whether this DLB-
associated effect on ribosomal DNA content was directly related to pathological changes 
in the cortex, samples from the DLB pathology-free cerebellum were analyzed.  In 
samples from this structure, direct correlations between individual values for various 
ribosomal DNA probes were observed confirming accuracy of our determinations (data 
not shown).  Surprisingly, in the cerebellum, ribosomal DNA content was lower in the 
DLB group.  Significant decreases of 0.55- and 0.42 fold control were observed for the 
5.8S- and 28S probes, respectively (Kruskal-Wallis ANOVA, p<0.01, Fig.7).  While the 
18S probe did not detect significant differences between the two groups, the genomic 18S 
content also showed a downward trend in DLB (Fig.7).  Therefore, DLB appears to be 
associated with instability of brain ribosomal DNA.  
 
Effects of Dementia with Lewy Bodies on methylation of the ribosomal DNA 
promoter region.  At least in cancer cell lines, amplification of ribosomal DNA may be 
associated with CpG hypermethylation [239].  As CpG methylation of the ribosomal 
DNA is associated with epigenetic silencing of ribosomal DNA copies, a combination of 
amplification and hypermethylation may help to keep the number of active ribosomal 
DNA copies constant [169].  Moreover, epigenetic silencing of ribosomal DNA may 
stabilize the inactive genes preventing recombination; conversely, de-silencing may have 
an opposite effect [77, 117].  Thus, methylation of the ribosomal DNA promoter region 




Figure 8. Similar methyl-cytosine content of the ribosomal DNA promoter region in the control- and 
Dementia with Lewy Bodies parietal cortex.   
A, Methylation of the ribosomal DNA promoter CpG#23 (position -9 from the transcription start site) 
content was determined using a methylation-sensitive enzyme HpaII and qPCR. B-C, Methylation of all 26 
CpG sites within the human ribosomal DNA promoter region (positions -186 to +26) was investigated 
using bisulfate sequencing. B, Average CpG methylation in the ribosomal DNA promoter. C,  Effect of 
DLB on distribution of CpG methylation across the ribosomal DNA promoter.  The data represent averages 
±SEM from 10 DLB- and 10 control- individuals. Individual values are depicted by squares; mean values 
are indicated by the lines intersecting the error bars.  In A and B, p values of the Kruskal-Wallis ANOVA 
are shown; in C, *, p<0.05 (SAM statistics).  Although CpG#7 and 17 appeared hyper methylated in DLB, 
the overall trend of CpG methylation across the 26 ribosomal DNA promoter CpGs was not significantly 




 methylation-sensitive restriction endonuclease HpaII or bisulfite sequencing.  
Methylation of the ribosomal DNA promoter was similar in the DLB- and the control 
group (Fig.8).  Therefore, in the DLB pathology-affected cerebral cortex, ribosomal DNA 
amplification is not associated with changes in CpG methylation of the ribosomal DNA 
promoter. 
 
Effects of template methylation on qPCR efficiency.  Methylation of ribosomal DNA 
is observed not only in the promoter region but also in the rRNA-coding exons that have 
been targeted for qPCR-based ribosomal DNA quantification.  Therefore a possibility 
exists that the apparent DLB-associated changes in ribosomal DNA content are due to 
altered methyl-CpG content in those regions if methylation affects qPCR amplification 
efficiency.  To exclude such a possibility, non-methylated ribosomal DNA fragment 
containing the 5.8S amplicon template was produced by PCR.  As the 5.8S amplicon 
contains 19 CpG sites including 3 in the reverse primer target sequence methylated 
template was generated in vitro using a non-selective CpG DNA methyltransferase 
M.SssI (Fig.9).  As compared to the unmethylated template, methylation only slightly 
increased qPCR efficiency resulting in about 10% overestimation of the template content.  
Therefore, even dramatic changes in CpG methylation of the ribosomal DNA templates 
are unlikely to explain up to 130% increases or decreases of ribosomal DNA content that 
were observed between control and DLB samples.Discussion and Conclusions 
 In this study, I probed for changes in ribosomal DNA content in the brain of old 
vs young subjects and DLB patients vs. controls using a qPCR based approach.  No 




Figure 9. Effects of template methylation on qPCR efficiency 
 A, PCR on genomic DNA was used to produce an unmethylated DNA fragment including a template for 
the 5.8S qPCR amplicon that revealed ribosomal DNA instability in DLB (red box, qPCR primers indicated 
by red arrows, PCR primers indicated by black arrows). DNA was then in vitro methylated with M.SssI 
DNA methyltransferase that indiscriminately targets all CpG sites. Note presence of multiple CpGs in the 
5.8S amplicon (opened and filled circles correspond to CpGs or methyl-CpGs, respectively; one of the 
CpGs is a part of an HpaII site). B, Methylation of a CpG that was part of an HpaII site was confirmed 
using HpaII-qPCR assay. When methylated DNA fragment was used as a template for 5.8S qPCR, 
ribosomal DNA content was overestimated by just 10% as compared to unmethylated template. Hence, 
differential methylation of ribosomal DNA templates of the qPCR amplicons is unlikely to account for 
DLB-associated changes in ribosomal DNA content. Data represent two independent experiments; error 




 individuals.  Our results are in agreement with a study which attempted to address this 
question using a hybridization based approach.  Significant increases in ribosomal DNA 
content were detected in the parietal cortex of DLB individuals compared to age matched 
controls with increases ranging from approximately 1.5 to 2.2 fold.  The ribosomal DNA 
content of the cerebellum, a region which does not show pathological changes in DLB 
also contained altered ribosomal DNA content,  
however the direction of change was unexpectedly opposite that of the parietal cortex 
with a decrease of approximately 50% in two of the three probed regions.  
 A prior AD study produced similar results for the parietal cortex as both DLB and 
AD contained elevated ribosomal DNA content [206].  Moreover, the magnitude of 18S 
increase, approximately 50%, was similar to what has been documented in mild cognitive 
impairment and late stage AD which contained increases of 50% and 69%, respectively.  
In contrast, the DLB’ cerebellum contained a significant decrease in ribosomal DNA  
content, a finding which was not apparent in AD. However, it is important to note that 
this decrease was documented in the 5.8S and 28S ribosomal DNA regions which were 
not probed in the prior AD study.  The 18S region trended down in DLB but did not 
reach statistical significance.  Thus, comparing the DLB and AD cerebellum is at least 
partially inconclusive.  Interestingly, a similar trend has been documented in the genomic 
content of another highly repetitive sequence, the telomere.  In both AD and DLB 
telomere length was decreased in peripheral blood leukocytes, and, at least in the case of 
AD, increased in the hippocampus, a brain structure directly affected by AD pathology 
[29, 127, 243]. 
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 It is important to note that all data obtained in this study are based on genomic 
DNA which was extracted from tissue containing a mixed population of cells.  It is 
unclear which cell type or types are contributing to these findings.  Homologous 
recombination is believed to be the major mechanism behind ribosomal DNA instability 
and readily occurs during both mitosis and meiosis.  Therefore, such requirements 
suggests inappropriate activation of homologous recombination is occurring in cycling 
cycles [233]. 
 Recent literature suggests homolgogous recombination may not be the only 
possibility for my findings.  I propose three potential explanations.  First, as stated 
previously, this phenomenon could be occurring in cycling cells, suggesting that the 
findings are the result of reactive gliosis, a condition which is involved in both AD and 
DLB [17, 215].  Reactive gliosis involves mitosis and the rapid proliferation of glia, thus 
allowing homologous recombination to occur.  Theoretically, expansion of ribosomal 
DNA in reactive glia could aid in their ability to rapidly proliferate. A similar 
phenomenon is known to occur in amphibian and insect oocytes [21, 141, 174].  
 A second potential explanation is that homologous recombination occurs in 
response to reactivation of the cell cycle in post-mitotic neurons.  Multiple studies have 
documented at least partial cell cycle reactivation in AD pathology associated areas [27, 
261, 262].  Proteins from all phases of the cell cycle have been shown to be increased in 
AD.  Moreover, the frequency of aneuploidy has also been shown to be increased in AD 




 Lastly, canonical homologous recombination may not be necessary for 
fluctuations in ribosomal DNA copy number.  Interestingly, emerging data have 
identified homologous recombination-like activity in post-mitotic cells [65, 66].  In these 
cells, UV radiation induced double strand breaks which were repaired using a mechanism 
that involved short segmental contact between homologous chromosomes in a 
transcription- and ATM- dependent manner.  Theoretically, such a repair mechanism 
could be sufficient to produce effects similar to canonical homologous recombination.  
Moreover, the unique repetitive nature of the ribosomal DNA and the general structure of 
the nucleolus may allow for recombination in the absence of mitosis.  The cell’s 600 
copies of ribosomal DNA, which are arranged as tandem arrays on 5 separate 
chromosomes, are all in close physical proximity due to their nucleolar localization.  
Such an atypical orientation and the relatively high rates of transcription which occur in 
this region may make the generation of sister chromatids unnecessary for homologous 
recombination-like activity. 
 While the effects of altered ribosomal DNA content in the human brain are 
unclear, findings from lesser species and mammalian cell lines may potentially provide 
insight.  Surprisingly, the rate of ribosomal biogenesis may not be subject to large 
alterations under the documented circumstances.  It is known that most multicellular 
species contain a large excess of ribosomal DNA copies of which a large percentage is 
epigenetically silenced [52].  Thus, an expansion of ribosomal DNA copies would most 
likely add to this epigenetically silenced pool and cause little, if any, alterations in the 
rate of ribosomal biogenesis.  Moreover, cells appear capable of withstanding limited 
ribosomal DNA loss.  Germ line deletions of significant ribosomal DNA quantities in 
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both flies and chickens still produced viable organisms [45, 194].  For example in the 
chicken study, embryos with 66% of the normal ribosomal DNA content grew and 
developed as expected [45].  Thus, a portion of the cellular ribosomal DNA content is 
unnecessary for ribosome synthesis even during the organism’s most demanding periods 
of growth.  Taken together, these reports suggest that any potentially detrimental effects 
of ribosomal DNA copy loss are potentially related to functions other than ribosomal 
biogenesis. 
 Interestingly, in lower organisms, manipulation of ribosomal DNA content has 
identified several non-coding functions.  In the aforementioned fly studies, ribosomal 
DNA variation directly influenced heterochromatin content [195].  Moreover, in a mouse 
cell line, loss of the nucleolar silencing complex component TIP5 lead to a decrease in 
both heterochromatin content at major- and micro- satellite DNA and loss of ribosomal 
DNA content [77].  Taken together, such findings suggest that ribosomal DNA instability 
may affect mammalian heterochromatin content.  Moreover in ribosomal DNA deficient 
flies, changes in euchromatin and gene expression changes were detected [193].  
Furthermore, clusters of genes linked to both mitochondrial function and lipid 
metabolism were prominent in the population of altered genes [193].  Interestingly, 
alterations in both of these areas are common to both AD and DLB [18, 39, 184, 212].   
 In yeast it has been proposed that silent ribosomal DNA copies function as a sink 
for mediators of the DNA damage response.  Kobayashi proposed a model in which 
ribosomal DNA loss, which is known to be associated with replicative senescence, would 
release DNA damage response mediators in a manner analogous to telomere shortening 
triggering the DNA damage response [117].  Alternatively, increased ribosomal DNA 
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content could raise the threshold for DNA damage response activation.  In support of 
Kobayashi’s theory, it was demonstrated that yeast with larger ribosomal DNA content 
were more resistant to the DNA damaging agent methyl methanesulfonate than those 
with less ribosomal DNA content.  While this possibility has not been addressed in 
mammalian cells, nucleolar sequestration of other stress mediators is known.  Heat Shock 
Protein 70 (HSP70), MDM2, and the Von Hippel Lindau (VHL) protein have been 
documented to be sequestered in the nucleolus via their affinity for non-coding RNAs 
generated from the intergenic spacer region of the ribosomal DNA unit [10].  Therefore, 
changes in ribosomal DNA content may affect the cellular stress response. 
 While more work needs to be done to identify the consequences of ribosomal 
DNA instability in the human brain, we propose a working model based on the effects of 
altered ribosomal DNA documented in the literature (Fig.10).  I propose DNA damage 
induced genomic instability as a general component of the degenerating brain.  Under 
these conditions, ribosomal DNA content would be disproportionally affected due to its 
tandem array arrangement, the high rate of ribosomal DNA transcription, and the 
physical proximately of all 10 ribosomal DNA arrays.  In this model homologous 
recombination or “homologous recombination-like” activity would produce instability in 
ribosomal DNA content.  This instability would ultimately alter heterochromatin levels, 
euchromatin gene expression, and the DNA damage response.  Increases in ribosomal 
DNA content would increase the level of heterochromatin, increase ribosomal DNA’s 
ability to influence euchromatin gene expression, and increase DNA damage response 
resistance.  Conversely, loss of ribosomal DNA would produce the opposite effect. 




Figure 10. A hypothetical model summarizing possible causes and consequences of ribosomal DNA 
instability. 
The DNA damage-stimulated homologous recombination is a likely cause of ribosomal DNA instability in 
the degenerating brain. The moderate changes in ribosomal DNA copy number as those reported here are 
not expected to significantly affect ribosomal biogenesis. Instead, ribosomal biogenesis-independent 
functions of ribosomal DNA may be affected including control of the DNA damage response, maintenance 
of heterochromatin, and expression regulation of the non-ribosomal RNA genes that are located in the 
euchromatin. One can speculate that higher content of ribosomal DNA may support cell survival by 
suppressing the DNA damage response, stabilizing chromatin and stronger regulatory control of the 
euchromatic genes. Conversely, lower ribosomal DNA content may have opposite effects on cell sensitivity 
to DNA damage as well as other forms of stress by enhancing the DNA damage response, reducing control 
over euchromatin gene expression and destabilizing the chromatin architecture. Thus, ribosomal DNA 
amplification in the degenerating regions of the DLB- or Alzheimer’s- disease brain may be a consequence 
of increased genotoxic stress. In turn, cells with the higher genomic content of ribosomal DNA may 




 application of a selection pressure, such as the enhanced DNA damage which is common 
to the DLB and AD parietal cortex, would select for increased ribosomal DNA content 
and promote cell survival. Thus in the DLB cortex, which experiences significantly larger 
levels of oxidative stress and synucleinopathy, the magnitude of DNA damage would be 
large enough to select for increased quantities of DNA.  In the case of the DLB 
cerebellum, low level potentially undetectable DNA damage would still induce genomic 
instability.  However, no such selection pressure would exist and genomic instability 
would present as a loss of ribosomal DNA.  Moreover, neurodegeneration associated cell 
loss would remove less resilient cells thus further enriching the total population with cells 
containing higher ribosomal DNA content.  
 In summary, we have not detected any age related changes in ribosomal DNA 
content.  However, we have identified a second neurodegenerative disease, DLB, with 
increased ribosomal DNA content in the parietal cortex.  Moreover, we unexpectedly 
documented decreased ribosomal DNA content in the pathology-free cerebellum 
specifically for the 5.8S and 28S segments.  Therefore, we propose that genomic 




PERSISTENCE OF BRAIN PRE-RRNA AND NUCLEOLAR PRESENCE OF 
NEURONAL NUCLEOPHOSMIN AFTER DEATH 
Introduction 
 It has been proposed that the neuronal nucleolus acts as a stress sensor and 
regulator of cell death [91, 162].  Dysfunction of the nucleolus and the subsequent 
activation of the ribosomal stress response have been implicated in multiple 
neurodegenerative and neurodevelopmental diseases.  Such findings have prompted 
studies which probed nucleolar stress markers in post mortem human brain tissue [81, 
166, 206, 214]. 
 A major concern with these studies is the reliability of nucleolar stress markers in 
post mortem tissue.  In response to practically all causes of death, the brain dies from 
nutrient and oxygen deprivation when the heart fails to supply adequate blood flow.  It is 
well documented that nucleolar activity is directly related to overall cellular well-being 
and is highly responsive to factors including cellular energy levels, serum starvation, and 
hypoxia [52, 76, 126, 170, 182, 228, 260].  Thus, post mortem-associated brain ischemia 
may represent a significant source of nucleolar stress. 
 The stability of nucleolar stress markers in post mortem material has not been 
addressed in the literature.  Several studies have probed both general protein stability and 
the stability of epigenetic markers in post mortem tissue, but importantly these studies did
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 not focus on the nucleolus.  It appears that, as expected, increased protein degradation 
occurs with increased PostMortem Interval (PMI) and also during storage [56, 178].  
However unexpectedly, these studies demonstrated that not all proteins degrade at the 
same rate.  Moreover, a proteomics based study conducted a year later produced similar 
findings [38].  With regard to epigenetics, histone tail acetylation was found to be highly 
unstable while on the other hand DNA methylation was unchanged [15, 16].  However, 
the aforementioned methylation study did not investigate genes which are known to be 
regulated by energy status.  Therefore, the specific set of genes investigated by 
Barrachina et.al. (2012) may be a poor predictor of the rDNA promoter.  Lastly, the 
enzymatic activity of acetyltransferases and methyltransferases were not significantly 
altered in response to increasing PMI [178].  Thus, the mechanisms for epigenetic 
modification are potentially active for many hours after death. 
 The use of post mortem tissue is especially important for neurodegenerative 
disease research.  Despite its flaws, post mortem tissue will in some cases be the best 
option for molecular studies.  With regard to the vast majority of neurological conditions, 
non-post mortem human tissue samples are simply not available for research.  In general, 
the only major exceptions to this rule are cancerous tumors, benign growths (such as 
neurofibromas) and temporal lobectomies [155].  The later condition is reserved for 
severe cases of epilepsy [253].  Moreover, for some neurodegenerative diseases the use 
of transgenic animals is severely limited and in such cases post mortem human tissue 
may be the only option for brain based molecular studies.  For instance, some diseases, 
such as Dementia with Lewy Bodies, have not been linked to genetic mutations.  
Therefore, the generation of animal models can be problematic and in some cases 
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impossible.  Additionally, some mutations appear to be specific to humans and have little 
to no phenotype in rodents.  Such, a condition is evident for Ataxia Telangiectasia and 
Parkin mutations which are associated with familial Parkinson’s disease [134, 203].  
Lastly, one must also consider that familial neurodegenerative disease mutations may not 
be representative of sporadic disease and as such may only model discreet portions of 
disease cascades.  Thus, despite the clear imperfections in post-mortem tissue- based 
studies they are still essential for the study of human neurodegenerative disease. 
 Therefore, I investigated the stability of rDNA promoter methylation, 
nucleophosmin localization, pre-rRNA content, and rDNA locus stability in rodent brain 
tissue in response to various experimentally controlled post mortem intervals.  
Additionally, we probed the constancy of pre-rRNA and nucleophosmin localization in 
response to energetic failure in living neurons. 
Materials and Methods 
Post Mortem Ischemia.  All animal experiments complied with University of Louisville 
Institutional Animal Care and Use Committee (IACUC) protocols and National Institute 
of Health (NIH) guidelines. Six week old male Sprague Dawley rats (Harlan- 
Indianapolis, IN) were euthanized using CO2.  The carcasses were left at ambient 
temperature for various times before tissue collection.  Cerebral cortex samples for 
RNA/DNA studies were frozen on dry ice and stored at -80C prior to nucleic acid 
isolation.  For immunofluorescence whole brains were placed in 4% Paraformaldehyde 
overnight followed by storage in 0.12 M Millonig’s phosphate buffer. 
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Nucleic acid isolation and PCR.  For pre-rRNA quantification, total RNA was isolated 
using TRI Reagent (Invitrogen) according to manufacturer’s protocol.  Quantitative 
Reverse Transcriptase-PCR (qRT-PCR) that employed ΔΔCt analysis was performed as 
described previously [106].  For assessment of rDNA locus stability genomic DNA was 
isolated using the DNeasy blood and tissue kit (Qiagen).  Quantitative PCR (qPCR) that 
employed standard curve analysis was performed as described previously [81].  Primer 
nucleotide sequences are listed in Table 4. 
Cell culture experiments. Primary cortical neurons were isolated from Sprague-Dawley 
rats (Harlan-Indianapolis, IN) on post-natal day 0 and cultured as described previously 
[78].  On day in vitro (DIV) 6-7, cells were treated with 10 mM Sodium Azide and 6 mM 
2-deoxyglucose or 250 µM glutamate which were dissolved in culture medium prior to 
use.  
Immunofluorescence. Immunostaining was performed on paraformaldehyde-fixed 
primary cells or sections of paraformaldehyde-fixed brains as previously described [207] 
except the primary antibody was mouse monoclonal anti-b23 (Clone number FC82291, 
Sigma, dilution 1:1,500). 
HpaII Restriction Endonuclease Methylation Analysis.  HpaII methylation analysis was 
performed as described previously [81].  Briefly, genomic DNA was cleaved with the 
methyl-sensitive restriction endonuclease HpaII and analyzed by qPCR using the 
standard curve methodology.  For normalization, an amplicon was designed in a region of 
the external transcribed spacer 1 (ETS1) which did not contain an HpaII cleavage site.  
Primer sequences are listed in Table 4.    
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Table 4.  Chapter III primers 
Experiment Amplicon Direction Sequence (5’-3’) 
Pre-rRNA 45S pre-rRNA ETS1 Forward TGGGGCAGCTTTATGACAAC 
Quantification  Reverse TAGCACCAAACGGGAAAACC 
 45S pre-rRNA ITS1-5.8S Forward CGCTCACACCTCAGATAACC 
  Reverse CTAGCTGCGTTCTTCATCG 
 18S rRNA Forward GTTGGTTTTCGGAACTGAGGC 
  Reverse GTCGGCATCGTTTATGGTCG 
rDNA Genomic 28S rRNA Genomic Forward CCTCTGGCATGTTGGAACAATGTAGG 
Stability  Reverse CCAGCCCTTAGAGCCAATCCTTAT 
 tRNA-KCTT Genomic Forward CTAGCTCAGTCGGTAGAGCATG 
  Reverse CCAACGTGGGGCTCGAAC 
rDNA Methylation Promoter HPAII Forward GTGAGCACTCAGGGTTCTAAG 
  Reverse CTCCAGGTACAATAAGGACAG 
 28S HPAII Forward CCTCTGGCATGTTGGAACAATGTAGG 
  Reverse CCAGCCCTTAGAGCCAATCCTTAT 
 rDNA Normalizer- No HPAII Forward TGTGTGTGTGGCAGTGTTAG 





 Given that pre-rRNA is rapidly processed and that RNA Polymerase I is highly 
sensitive to hypoxia and cellular energy content, we hypothesized that pre-rRNA levels 
would decline sharply following euthanasia [75, 170, 182].  To test this hypothesis qRT-
PCR was used to probe pre-rRNA levels at 3- and 12 h post mortem.  As I anticipated 
degradation, two separate regions of the transcript were probed.  qRT-PCR amplicons 
probing both the 5’ external transcribed spacer (5’ETS) and the internal transcribed 
spacer 1 (ITS1) regions of the pre-rRNA transcript were utilized.  Indeed, pre-rRNA 
levels were significantly decreased in response to increasing PMI, however the rate of 
decline was unexpectedly low (Fig.11A, p<0.01 for 5’ETS and p=0.01 for ITS1, one-way 
ANOVA, factor PMI).  Pre-rRNA was not significantly decreased at 3h PMI, although 
the ITS1 regions trended down.  Amplicons in both the 5’ETS and ITS1 regions revealed 
pre-rRNA declines at 12 h (Fig.11A, p<0.05 for 5’ETS and p<0.05 for ITS1).  However, 
the decreases were modest with levels approximately 70% of controls still present at this 
time.  Therefore, pre-rRNA levels are not static after death, but the rate of decline does 
not phenocopy the sharp declines which are seen after treatment with RNA polymerase I 
inhibitors such as actinomycin-D (Act-D). 
 Re-localization of the nucleolar protein NPM into the nucleoplasm is a commonly 
used marker of nucleolar stress [235].  Therefore, the status of the nucleolar NPM was 
monitored in the cerebral cortex at various PMIs.  Nucleolar NMP signal was visible in 
all cells at both 3- and 12 h PMIs.  Such observations are consistent with moderate 
declines of pre-rRNA as NPM localization to the nucleolus is highly dependent on its 




Figure 11. Effects of post mortem ischemia on brain cell nucleoli. 
Rats were euthanized and left at ambient temperature for the indicated post mortem interval (PMI). A,B, In 
neocortex, pre-rRNA levels were determined using quantitative qRT-PCR that probed two amplicons 
including one from the 5’ External Transcribed Spacer (5’-ETS) and one from the Internal Transcribed 
Spacer-1 (ITS1). 18S rRNA was used for normalization.  Note moderate declines of pre-rRNA levels.  
Sample size is n=9 for each group. Error bars are SEM, p<0.05: *. B, Representative images of brain cells 
from neocortex that were stained for nucleolar Nucleophosmin(NPM).  NPM-positive nucleoli are present 
at both 3- and 12 h PMI. A small fraction of neuron-like cells contained NPM not only in the nucleoli but 
also in perikarya and proximal neurites.  C, HpaII restriction analysis of 2 rDNA CpG sites, one contained 
the promoter region and one contained within 28S in brain samples from neocortex.  PMI had no 
significant effects on methylation of either CpG site.  D, Quantitative PCR with Genomic DNA was used to 
determine the effect of increasing PMI on genomic rDNA content in neocortex . PMI had no significant 




 declines of pre-rRNA [171].  Thus, in brain cells, post mortem ischemia does not present 
as canonical nucleolar stress. 
Unexpectedly, NPM was also observed in the perikarya and in proximal dendrites of 
neuron-like cells at both 3- and 12 h PMIs (Fig.11B). In such cells, nucleolar NPM 
staining was still visible.  However, most cells retained the entire NPM signal in the 
nucleoli/nuclei.  These findings suggest that in most cells of the cerebral cortex, nucleolar 
NPM presence is relatively well preserved after death.  
 The density of DNA methylation and specifically gene promoters is believed to 
correlate with transcriptional activity [238].  As prior studies have shown that inactive 
rDNA copies contain increased cytosine methylation, we probed two cytosine-phosphate-
guanosine (CpG) sites in the rDNA gene [169].  The first site was one of the 5 CpGs 
contained within the rat rDNA gene promoter, while the second was contained within the 
28S rRNA region.  Neither CpG displayed altered methylation levels at any time point 
during the 12 hour analysis (Fig.11C). 
 Dr. Pietrzak and I have documented abnormalities in rDNA gene content in 
neurodegenerative disease [81, 206].  While this feature is not linked to cellular energy 
status like the 3 prior stress markers, the multi-copy rDNA locus may still be sensitive to 
nuclease activity during the post mortem period.  Therefore we probed for changes in 
rDNA content in response to increasing post mortem intervals.  Importantly, genomic 




 Next it was investigated whether similar preservation of pre-rRNA and nucleolar 
NPM would be observed in primary rat cortical neurons in response to chemical 
ischemia.  After a one hour exposure to sodium azide and 2-deoxyglucose, pre-rRNA 
levels were moderately reduced as revealed with the ITS1- but not the 5’ETS-amplicon 
(67% control, p=0.001, u-test, Fig.12A). Consistent with such a good preservation of pre-
rRNA, chemical ischemia-exposed neurons still displayed nucleolar NPM (Fig.12B).  
However, in most cells a portion of NPM was also found in the perikarya and proximal 
dendrites. 
 The relatively modest impact of ischemia on pre-rRNA levels and nucleolar 
residence of NPM was unexpected given the high sensitivity of RNA Pol I to energy 
shortage.  However, it is also possible that energy failure may mask the consequences of 
RNA Pol I inhibition by simultaneous disruption of pre-rRNA processing.  To test such a 
possibility neurons were pre-treated with actinomycin D (Act-D) to prevent de novo 
synthesis of pre-rRNA.  After 15 min, cells were exposed to chemical ischemia for one 
hour.  Act-D treatment alone reduced pre-rRNA levels to 9% of control for both the 
5’ETS and ITS1 probe.  In neurons treated with Act-D and chemical ischemia declines of 
pre-rRNA were significantly attenuated as levels increased to 40% and 24% of controls 
for the 5’ETS- and ITS1 amplicons, respectively (Fig.12C, p<0.01, both amplicons u-
test).  Moreover, chemical ischemia attenuated nucleoplasmic release of NPM.  However, 
the nucleolar NMP signal appeared reduced and perikaryal/dendritic NPM signal was 




Figure 12. Effects of chemical ischemia on the neuronal nucleolus. 
On DIV6 rat primary cortical neurons were treated with 10 mM aodium Azide and 6 mM deoxyglucose for 
1 h to induce chemical ischemia (CI). A, Pre-rRNA levels were determined using quantitative qRT-PCR 
that probed two regions of the transcript, one from the 5’ External Transcribed Spacer (5’-ETS) and one 
from the Internal Transcribed Spacer-1 (ITS1).  Modest declines of pre-rRNA were detected in the ITS1 
region.  B, Representative images of chemical ischemia treated primary cortical neurons.  Chemical 
ischemia was sufficient to induce extra-nuclear appearance of NPM, but nucleolar NPM was still present.  
C and D, Cells were treated with Actinomycin-D (act-D) for 15 minutes prior to chemical ischemia.  C, 
Chemical ischemia attenuated declines of pre-rRNA in response to Act-D.  Error bars are SEM, p<0.01: **.  
D, Representative images of primary cortical neurons treated with Act-D and chemical ischemia.  The Act-




 Our results suggest that some frequently used parameters to probe the status of 
ribosomal biogenesis and/or the integrity of the nucleolus are remarkably stable for up to 
12 h after death.  These include the nucleolar localization of NPM, methylation of the 
rDNA promoter and the stability of the genomic rDNA locus.  However, moderate 
declines of pre-rRNA which appear to increase with PMI were detected.  Thus, caution 
should be used when attempting to measure this parameter in post mortem samples.  
However, given the slow rate of decline such studies may potentially be feasible if PMIs 
can be carefully matched. 
 Moderate losses of pre-rRNA after death may be the result of energy independent 
degradation rather than the canonical pre-rRNA processing.  In support of this concept, in 
mice, decapitation was shown to deplete brain ATP levels within seconds or minutes 
depending upon the age of the animal [149].  Such a rapid rate of energy depletion argues 
strongly against energy dependent pre-rRNA processing occurring multiple hours after 
death.  Moreover, we demonstrate that in primary neuronal culture energetic depletion 
increases the retention of pre-rRNA following pharmacological inhibition of RNA 
Polymerase I.  Such findings are consistent with the demonstrated requirements for ATP 
in multiple steps of ribosomal biogenesis and rRNA processing, including ATP 
dependent DExH-box enzymes which facilitate RNA cleavage [124].  Given the 
ubiquitous nature of energy independent RNases and the energetic requirements for 
canonical pre-rRNA processing, I speculate that post mortem loss of pre-rRNA is the 
result of non-specific degradation rather than legitimate processing.  On the other hand, it 
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is also conceivable that a portion of processing enzymes contain low levels of activity in 
the absence of ATP.   
 The ability of NPM to demarcate the nucleolus was unaltered by increasing PMI 
suggesting that it can be used to assess the presence of nucleolar stress in post mortem 
samples collected at least up to 12 h after death.  The preservation of nucleolar NPM is 
presumably the result of the previously discussed pre-rRNA retention.  While nucleolar 
assembly is not fully understood, the nucleolus is believed to form based on multiple 
proteins having a high binding affinity for pre-rRNA and/or other ribosomal proteins 
[191].  This feature has prompted some to refer to the nucleolus as an “organelle formed 
by the act of building a ribosome”  [171].  In support of this hypothesis’, pre-rRNA was 
shown to be an essential component of nucleolar assembly and in its absence nucleoli 
cannot form [74].  Moreover, the three dimensional size of nucleoli is believed to directly 
related to the quantity of pre-rRNA contained within its borders [224].  Lastly, nucleolar 
presence of NPM is strictly dependent on pre-rRNA binding as its loss from the nucleoli 
after Pol1 inhibition is due to plunging pre-rRNA levels [93]. 
 Of note, energy deprivation prevented the nucleoplasmic translocation of NPM 
after Pol1 inhibition in HeLa cells [57].  As in neurons, nucleolar retention of NPM was 
likely due to increased half-life of pre-rRNA. Hence, our observations on the effect of 
PMI on nucleolar NPM are likely applicable to studies of other organs besides brain. 
 Transport of NPM is not fully understood, but the process is known to be 
regulated by multiple localization signals, RAC1 and cellular ATP and GTP levels [36, 
57, 58, 188].  Thus the accumulation of extra nuclear NPM could be a simple 
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mislocalization mediated by energy failure.  However, such a mislocalization may have 
further consequences for cell survival.  Interestingly, extranuclear NPM has been 
proposed to play a role in cell death.  Surprisingly, NPM has been proposed to play 
contradictory roles depending on the context.  In a rodent model of stroke, NPM has been 
implicated as a chaperone for the pro-apoptotic BCL2 Associated X Protein (BAX) [111, 
249].  Conversely, in cultured rodent neurons, anti-excitotoxic effects were also 
demonstrated as NPM inhibited the Seven In Absentia Homolog 1 (SIAH1)- 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) death cascade [136, 159]. 
 rDNA methylation and gene content were both unchanged in response to 
increasing post mortem interval, suggesting there measurements are relatively free from 
post mortem artifact.  Our methylation findings are in agreement with Barrachina et.al 
(2009) who demonstrated that methylation of neurodegenerative disease related genes 
was stable in the post mortem brain [15].  Importantly, our results support the validity of 
several prior studies which reported the effect of brain pathologies on rDNA status.   
Increased rDNA promoter methylation was found in the AD and suicide brain, but not in 
DLB [81, 166, 206].  Additionally, rDNA gene content was found to be increased in both 
AD and DLB [81, 206].  With regard to the PMIs in these studies, all donors in the AD 
and DLB reports had PMIs within the 12 h time frame of our experiments and most were 
under 4 h.  Alternatively, the suicide study contained PMIs which averaged 
approximately 24 h.  As this was double our latest time point, caution should be used if 
attempting to extrapolate our results to such high PMIs. 
 Separate from the methodological concerns addressed in this study is the larger 
concept that energetic failure can mask nucleolar stress.  Such a phenotype suggests that 
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the ribosomal stress response could indeed be activated in conditions such as stroke or 
neurotrauma, despite the persistence of punctate nucleolar NPM localization.  As the 
ribosomal stress response is centered on stoichiometric imbalances of ribosomal 
components, it’s feasible that the dual inhibition of pre-rRNA synthesis and pre-rRNA 
processing could synergistically produce deficits in rRNA content [114].  The concept of 
ribosomal stress in the absence of NPM translocation should also be considered in 
situations other than energetic failure.  Numerous neurodegenerative diseases contain 
evidence for nucleolar involvement despite the absence of reports demonstrating 
canonical nucleolar stress [47, 48, 122, 135, 214, 252].  Such a condition suggests that 
these diseases should be re-evaluated with additional stress markers as the dispersion of 
NPM appears to be sufficient, but importantly not necessary for the induction of 
ribosomal stress.  Thus, these diseases could indeed contain induction of ribosomal stress 
while still maintaining punctate nucleolar NPM staining. 
 In summary, at least up to 12 h after death, brain cell nucleoli are relatively well 
preserved.  Such preservation is likely due to ischemia-associated disruption of rRNA 
processing and the subsequent stabilization of pre-rRNA.  Therefore, studies of post-
mortem samples that were collected at PMIs lesser than 12 h should provide a relatively 
accurate insight into the status of the nucleolus in chronic brain pathologies. Conversely, 
in such acute conditions as stroke and neurotrauma, energy failure may mask signs of 
disrupted ribosomal biogenesis.  Hence, there is a need to identify novel parameters of 





THE ROLE OF RIBOSOMAL PROTEIN L11 IN NEURONAL DEATH 
Introduction 
 The nucleolus is a vital component of neuronal function.  While it is well known 
that the nucleolus is the center of ribosomal biogenesis, its overall role in neuronal well-
being is considerably larger.  Nucleolar activity has been linked to neuronal growth 
capacity, maintenance of size upon reaching maturity, and regeneration after injury [72, 
115, 130, 231].  Therefore, adequate nucleolar activity appears to be necessary to prevent 
neuronal atrophy and synapse loss [198].  Moreover, cells have evolved ribosomal 
protein-mediated stress responses which monitor the fidelity of ribosomal biogenesis. 
 Ribosomal protein mediated stress responses appear to have evolved for two 
reasons.  First, ribosomal biogenesis is the largest consumer of cellular energy in dividing 
cells [124]..  Thus, error prone ribosome synthesis has the potential to waste considerable 
amounts of cellular resources.  Second, in multicellular organisms ribosomal stress 
appears to have evolved into a tumor suppressive pathway.  While more work is needed 
to clearly demonstrate ribosomal stress as a bona fide tumor suppressive mechanism, 
current reports suggest that it does indeed inhibit myc-driven oncogenesis [114, 153].  
The precise mechanisms for such an effect are unclear; however ribosomal stress is 
known to be centered on stoichiometric imbalances of ribosomal components.  Therefore, 
it is likely that oncogenes differentially stimulate the production of certain ribosomal 
components relative to others.  In support of this concept, a constitutively
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 active HRAS mutant was shown to induce ribosomal stress by stimulating pre-rRNA 
transcription beyond the cells capacity for processing [187]. 
 Nucleolar Stress and ribosomal stress appear to be separate pathways which result 
in distinct outcomes in many cell types.  Traditionally, these terms have been used 
interchangeably, but current reports suggest that they are not identical, despite the fact 
these pathways partially overlap.  Classically, nucleolar stress has been considered to be 
an inhibition of RNA polymerase I which releases several nucleolar proteins, including 
nucleophosmin and nucleostemin into the nucleoplasm and induces apoptosis in most cell 
types [11, 25, 106].  Alternatively, ribosomal stress is the result of stoichiometric 
imbalances in ribosomal components and in most cell types induces p53 mediated cell 
cycle arrest [63, 64, 114, 187].  Nucleolar stress is sufficient, but not necessary for the 
induction of ribosomal stress as multiple mechanisms for impairing the stoichiometry of 
ribosomal components are possible.  For example, loss of a single ribosomal protein will 
induce ribosomal stress while having no effect on nucleolar morphology [63].  
Essentially, nucleolar stress appears to encompass the entire ribosomal stress response, 
but also includes the release of a second layer of stress mediators not seen with simple 
stoichiometric imbalances of ribosomal components.  The pro-apoptotic protein Myb 
binding protein 1a (MYBBP1A) is one such mediator [125, 126]. 
 Nucleolar stress is known to induce apoptosis in immature neurons [106, 198].  
Interestingly, this response is developmentally restricted as mature neurons do not 
undergo apoptosis under such conditions [198, 207].  They do however still accumulate 
p53 [214].  The effect of ribosomal stress on neuronal cell death has not been 
investigated.  Such a condition may be of greater relevance to neurological disease as 
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evidence for catastrophic nucleolar failure is rare, but numerous studies have 
demonstrated more subtle impairments of ribosomal biogenesis in neurodegenerative 
disease [47, 48, 79, 129].  Moreover, two neurodevelopmental diseases involving mental 
retardation and microcephaly, Bowen Conradi Syndrome and Alopecia, Neurological 
Deficits and Endocrinopathy (ANE) Syndrome have been linked to genes with 
documented roles in ribosomal subunit assembly [9, 189].  Such diseases would be 
expected to engage the ribosomal stress response. 
 Perhaps the best described mediator of nucleolar- and ribosomal stress in non-
neuronal cells is RPL11.  Multiple reports suggest the 5S ribonucleoprotein particle (5S 
RNP), a subcomponent of the large ribosomal subunit composed RPL11, RPL5, and the 
5S rRNA has been suggested to be the major stress effector [25, 49, 63, 64].  The current 
model suggests that the 5S RNP translocates from the nucleolus and binds the p53 
inhibiting protein MDM2 allowing for induction of p53-mediated cell cycle arrest or 
apoptosis [183].  Moreover, RPL11 has been demonstrated to have stress related “extra” 
ribosomal functions independent of its assembly in the 5S RNP and MDM2.  Such 
functions include binding the promoter of p53 target genes and directly binding p73 [266, 
267]. 
 Thus, there is a growing body of evidence suggesting the impairment of 
ribosomal biogenesis in both neurodegenerative- and neurodevelopmental disease.  
Moreover, RPL11 has been demonstrated to be a major regulator of both nucleolar- and 
ribosomal stress in non-neuronal cells.  Therefore we investigated RPL11 as a mediator 
of apoptosis in response to nucleolar stress, ribosomal stress, and other pro-apoptotic 
stimuli in primary cortical neurons. 
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Materials and Methods 
Antibodies.  The following antibodies were used in this study; anti-RPL11 (Proteintech, 
dilution 1:1,000), anti-NeuN (Millipore, dilution 1:500), anti-p53 (Santa Cruz dilution 
1:500), anti-phosho-Ser15-p53 (Cell signaling technologies, dilution 1:1,000), anti-
cleaved caspase 3 (Cell signaling technologies, dilution 1:1,000), Anti-Beta Actin 
(Sigma, dilution 1:2,000), anti-B23 (Sigma, dilution 1:1,500), chicken anti-beta-
galactosidase (Abcam, dilution 1:1,00) and goat anti-chicken 594 Alexa Fluor conjugated 
(Jackson Immunoresearch Laboratories, dilution 1:400),  
Plasmids  
Previously described plasmids.  The following previously described plasmids were used 
in this study; β-Gal (EF1αLacZ β-galactosidase)[98], p53 luciferase reporter gene (PG13-
Luc) [53], Temperature Sensitive p53 (p53val135) [173], dominant negative p53 (pCMV-
p53-DD)[223] 
Novel plasmids- RPL11-GFP (pEGFP-N1-RPL11) was cloned from cDNA obtained 
from a rat primary cortical neuron culture using primers containing EcoRI (forward) and 
BamHI (reverse) restriction sites.  RPL11 PCR product was inserted into the pEGFP-N1 
vector between the EcoRI and BamHI restriction sites in the multiple cloning site. 
pSUPER shRNA plasmids.  All shRNA plasmids were produced using the pSUPER 
RNAi system according to manufacturer’s protocol.  shRNA sequences were designed 
using shRNA or RNAi design tools available online from Invitrogen and genelink.com.  
Nucleotide sequences are contained in Table IV. 
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Drug treatment.  Camptothecin (CPT) and etoposide (Etopo) stock solutions were 
dissolved in DMSO and diluted to a 100X working solution with basal medium eagle 
(BME) prior to addition to culture media.  The final concentration of DMSO was 0.04% 
or less in all experiments.  Stock solutions of 5-fluorouracil (5-FU), ethynyl uridine (EU), 
and fluorodeoxyuridine (FdU) were dissolved in water and diluted with BME prior to 
addition to the culture media. 
Cell Culture and transfection.  Primary cortical neurons were cultured from Sprague 
Dawley rats (Harlan, Indianapolis IN) on post-natal day zero as previously described 
[78].  Culture medium consisted of BME supplemented with 10% heat-inactivated bovine 
calf serum (Hyclone, Logan, UT) 35 mM glucose, 1 mM L-glutamine, 100 U/mL 
penicillin and 0.1 mg/mL streptomycin.  For immunofluorescence studies, 0.5 x 10
6
 
neurons were seeded on poly-D lysine coated plastic cover slips contained in 24 well 
plates.  For quantitative RT-PCR studies, 2 x 10
6
 neurons were seeded in poly-D lysine 
coated 35 mm cell culture dishes.  2.5 µM cytosine arabinoside was added on day in vitro 
(DIV) 2 to prevent growth of non-neuronal cells.  All transfections used Lipofectamine 
2000 and occurred on DIV 4.   
Luciferase Reporter Gene and Beta Galactosidase Assays.  Luciferase and beta 
galactosidase enzymatic activities were determined using standard kits obtained from 
Promega (Madison, WI). 
Immunoblotting.  For western blotting primary cortical neurons were washed twice with 
PBS and lysed in SDS Page sample buffer.  Western blotting was performed as 
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previously described [106].  Antibodies and dilutions are listed in the antibodies portion 
of the methods section. 
Isolation of Nuclear fraction.  RPL11 immunoblots were conducted using nuclear lysates.  
To isolate the nuclear fraction, neurons were lysed by a 10 minute 4°C incubation with 
NTEN buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris pH=8.0, 0.5% NP-40) 
supplemented with Protease Inhibitor Cocktail Set III (calbiochem used at manufacturer’s 
recommended dilution) and 1 mM PMSF.  Lysates were centrifuged at 13,000 RPMs for 
20 minutes at 4°C to separate the cytoplasmic fraction.  Supernatant was removed and the 
pellet was resuspended in standard western blot SDS-sample buffer and boiled for 10 
minutes prior to use. 
Apoptotic Counts.  Beta galactosidase positivity was used as a marker of transfection.  
Nuclei were stained with Hoechst 22358 to visualize morphology.  Apoptosis was 
defined as condensed chromatin and significantly degenerated processes.  In most cases 
only cell bodies remained.  Cells counted as surviving contained large round 
uncondensed nuclei and no clear degeneration of processes.   
Northern Blot.  Northern blots were performed as previously described [137].  Nucleotide 
sequences are listed in Table IV.  5.8S probe was previously described [60]. 
Quantitative RT-PCR.  Quantitative RT-PCR was performed as previously described 
[106].  Primer sequences are listed in Table IV  
Ethynyl uridine incorporation.  Neurons were treated with 5-FU or vehicle for 2 hours 
prior to 50 minute incubation with 1mM EU.  After fixation cells were permeablized with 
0.5% triton in PBS for 30 minutes.  After washing, neurons were incubated with click 
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reagent (100 mM Tris, 1 mM CuSO4, 100 mM ascorbic acid, 50 µM Oregon green azide 
dye-Invitrogen) for 1 hour.  After washing, cells were then stained with Hoechst 33258 to 
visualize nuclei. 
MTT Assay.  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 




Table 5.  Chapter IV Nucleotide Sequences 
Experiment Amplicon/Target Direction Sequence (5’-3’) 
Pre-rRNA 45S pre-rRNA ETS1 Forward TGGGGCAGCTTTATGACAAC 
  Reverse TAGCACCAAACGGGAAAACC 
 45S pre-rRNA ITS1-5.8S Forward CGCTCACACCTCAGATAACC 
  Reverse CTAGCTGCGTTCTTCATCG 
 18S rRNA Forward GTTGGTTTTCGGAACTGAGGC 
  Reverse GTCGGCATCGTTTATGGTCG 
Northern Blot 5’ ETS Reverse TAGCACCAAACGGGAAAACC 
 ITS1 Reverse GGTTATCTGAGGTGTGAGCG 
 5.8S Reverse CTAAGAGTGGTACGAGGTCG 
shRNAs shRPL11-1 Forward GGTGCGAGAGTACGAATTA 
 shRPL11-2 Forward CTTCTCAGATACCGGCAAC 
 shRPL4-1 Forward CTTTGTTCACACCAACTTG 
 shRPL4-2 Forward GGCCTTCAGAAACATCCCT 
 shRPS6-1 Forward GATGATGTCCGCCAGTATG 





 First we tested the ability of RPL11 to modulate p53-mediated transcription 
relative to empty vector and RPL4 controls using a luciferase p53 reporter. We employed 
a temperature sensitive p53 construct which at temperatures greater than 32° C acts as a 
dominant negative.  Thus, we could quench p53 activity and allow RPL11 to accumulate 
for 24 h prior to an 18 h incubation at 30°C.  Over expression of RPL11, but not RPL4, 
was able to increase p53 transcriptional activity under such conditions (Fig.13B).  
Moreover, in cortical neurons that were treated with the nucleolar stress inducer CPT, 
nuclear content of RPL11 did not change (Fig.13C). Therefore, RPL11 is a good 
candidate for a mediator of the nucleolar stress response including p53-induced neuronal 
apoptosis.  
 To further evaluate this possibility, shRNAs were developed to knock down 
RPL11 (Fig.14A,B). As an additional control, validated shRNAs against L4 were also 
generated (Fig.14C).  We previously reported that shRNA mediated knockdown of RNA 
Polymerase 1 cofactor Transcription Initiation Factor 1A (shTIF) induces nucleolar stress 
and p53-mediated neuronal apoptosis [106].  Therefore, shTIF1A was used to examine 
the role of RPL11 in mediating the nucleolar stress. First, RPL11 knockdown did not 
affect shTIF1A-induced nucleolar stress and did not induce nucleolar stress by itself as 
determined by NPM immunofluorescence (Fig.13D).  Thus, the NPM fluorescent signal 
was reduced in the nucleolus and increased in the nucleoplasm in shTIF1A-transfected 
neurons and was not modified byRPL11 knockdown (Fig.14D).  However, RPL11 
knockdown attenuated shTIF1a-induced apoptosis (Fig.14E,F). The anti-apoptotic effects 




Figure 13. Overexpression of RPL11 increases p53-mediated transcription. 
A, General design of the temperature sensitive p53 (TS-p53) experiment.  B, On DIV 4, cells were 
transfected with PG13-Luc (p53 reporter gene), TS-p53, β-galactosidase for normalization, and RPL11-
GFP or RPL4-GFP or empty vector.  One representative experiment is shown.  24 hours after transfection, 
the temperature was lowered to 30°C for 18 hours thus allowing conformational change and activation of 
TS-p53.  Overexpression of RPL11 but not RPL4 was sufficient to increase p53 mediated transcription. C, 






Figure 14. Knockdown of RPL11 increases neuronal survival following shRNA induced nucleolar 
stress. 
A, Immunofluorescence validation of RPL11 shRNA constructs. B, Quantification of shRPL11 efficiency.  
Data represent the percentage of neurons which were double positive for RPL11-GFP and the β-
Galactosidase marker of transfection. C, Quantification of shRPL4 efficiency. D, Immunofluorescence 
demonstrating that shRPL11 does not prevent nucleolar disruption induced by shRNA mediated 
knockdown of Transcription Initiation Factor 1A (shTIF). E, Representative images depicting the criteria 
for quantification of neuronal apoptosis.  F, Quantification of neuronal apoptosis following shTIF induced 
nucleolar stress.  Knockdown of RPL11 significantly increased neuronal survival.  For post hoc 
comparisons p<0.001 is denoted by ***.  
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 rescue was observed with shL4. Therefore, RPL11 contributes to the activation of 
neuronal apoptosis in response to shTIF1A-associated nucleolar stress.  
 Previous work demonstrated that the DNA single strand break inducing 
chemotherapeutic CPT is an inducer of both nucleolar stress and apoptosis [106].  To 
strengthen the results described above, CPT was used as an additional inducer of 
nucleolar stress.  Similar to shTIF1A, CPT induced the translocation of NPM from the 
nucleolus to the nucleoplasm as determined by NPM immunofluorescence and was not 
modified by RPL11 knock down (Fig.15A).  RPL11 knockdown attenuated CPT induced 
apoptosis (Fig.15B,C)  Therefore, our results suggest that RPL11 is a genuine mediator of 
nucleolar stress-induced neuronal death as its knockdown attenuated apoptosis in two 
mechanistically different models. 
 After establishing the role of RPL11 in the neuronal nucleolar stress response, we 
next sought to determine its contribution to ribosomal stress, using two models which 
importantly do not disrupt the nucleolus. In non-neuronal systems, the RNA precursor 5-
FU induces such a state by perturbing the processing of pre-rRNA without interfering 
with RNA polymerase I activity [23].  We confirm that in rat cortical neurons 5-FU 
impairs the processing of pre-rRNA as determined by northern blot analysis (Fig.16A).  
First, 5-FU appeared to destabilize the initial 1kb region of the 5’ETS as both the full 
length 47S precursor and the 5’ETS-derived smaller fragment were sharply down-
regulated when a 5’ETS probe was used.  These changes were also observed with qRT-
PCR (Fig.16B). Processing defects were also indicated by the disappearance or reduction 
of more advanced intermediates including 12S, 20S, and 36S rRNAs (Fig.16A). 5-FU did 




Figure 15. Knockdown of RPL11 increases neuronal survival following camptothecin induced 
nucleolar stress. 
A, Immunofluorescence demonstrating that shRPL11 does not prevent nucleolar disruption induced by 24 
hour 2µM camptothecin treatment. B, Representative images depicting neuronal apoptosis. C, 
Quantification of neuronal apoptosis following 24 hour 1 µM camptothecin induced nucleolar stress.  
Knockdown of RPL11 significantly increases neuronal survival.  For post hoc comparisons p<0.001 is 





Figure 16. Characterization of 5-fluorouracil induced neuronal death. 
A, Northern blot analysis depicting rRNA processing following 4 hours 5-fluorouracil (5-FU) treatment. 
Multiple rRNA species which are generated during pre-rRNA processing are no longer apparent following 
5-FU treatment. B, 5-FU dose response depicting increasing inhibition of pre-rRNA levels as determined 
by quantitative rt-PCR measuring the 5’external transcribed spacers region against total 18S rRNA. C, 
Primary cortical neurons were treated with 100µM 5-FU or vehicle for 2 hours prior to a 1 hour hour 
incubation with 1mM ethynyl uridine.  Pre-treatment with 5-FU did not inhibit pre-rRNA synthesis as 
determined by immunofluorescence utilizing click chemistry to visualize EU incorporation into de novo 
synthesized RNA.  D, Western blot analysis of apoptosis related proteins following 5-FU treatment.  30 
hours of 5-FU treatment, but not 16 hour, increased total p53 and cleaved caspase 3 levels.  Interestingly, 
phosho-p53 was not induced at either time point.  F, MTT assay depicting the dose response and time 
course of 5-FU induced neuronal death.  For post hocs p<0.05:*, p<0.01:**, p<0.001:***.  Data for panel 
A was generated by Dr. L. Slomnicki and Dr. S. Ellis.  Data for panels B-E generated by Dr. A. Vashishta.  
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 precursor ethynyl uridine (EU) (Fig.16C).  Moreover, there was no evidence of NPM 
dispersion (Fig.16C). Such a ribosomal but not nucleolar stress was accompanied by 
accumulation of p53 (Fig.16D).  Interestingly, 5-FU did not increase p53 phosphorylation 
at Serine 15. However, it did activate apoptosis as indicated by increased levels of 
caspase-3 and reduced neuronal survival (Fig.16D,E).  Importantly, similar responses 
were not seen in control experiments which utilized 5-FU’s DNA precursor variant FdU.  
Lastly, 5-FU dosages of 10 µM and higher significantly reduced neuronal death 48 hours 
after treatment as determined by MTT assay (Fig.16E). 
 As the results detailed above suggest that 5-FU induces ribosomal stress in 
primary cortical neurons, we tested if knockdown of RPL11 would attenuate neuronal 
death.  Indeed, knockdown of RPL11 was able to completely rescue neuronal survival in 
response to 36 hours of 5-FU treatment (Fig.17C).  After RPL11 knockdown the rate of 
apoptosis dropped approximately 50% to below 30% which was equal to control levels 
(Fig 17C).  Interestingly, while 5-FU did not induce translocation of NPM, it did alter the 
nucleolar morphology.  The shape of nucleoli became increasingly irregular and less 
circular following 5-FU treatment (Fig. 17A). 
 It has been reported that knockdown of RPS6 induces ribosomal stress in the 
absence of nucleolar disruption in both mouse liver and cell lines [63].  Therefore, we 
sought to confirm similar results in primary cortical neurons and to determine if such a 
response is RPL11 mediated.  Nucleolar morphology was unaltered by shRNA mediated 
knockdown of RPS6 (shRPS6) as there was no evidence of NPM dispersion (Fig.17D).  




Figure 17. Knockdown of RPL11 increases neuronal survival following ribosomal stress induced 
apoptosis. 
A, Immunofluorescence demonstrating that 10 µM 5-FU does not induce nucleolar stress, but does alter 
nucleolar shape as they become less circular.  B, Representative images depicting the criteria for 
quantification of neuronal apoptosis.  C, Quantification of neuronal apoptosis following 36 hours of 10 µM 
5-FU treatment induced ribosomal stress.  Knockdown of RPL11 significantly increased neuronal survival.  
F, Immunofluorescence demonstrating that shRS6 does not induce nucleolar disruption.  E, Quantification 
of neuronal apoptosis following 48 hours of ribosomal stress induced by shRNA mediated knockdown of 
RPS6.  Knockdown of RPL11 significantly increased neuronal survival.  For post hoc comparisons p<0.001 




  shRPS6 induced significant neuronal apoptosis 48 hours after transfection and 
importantly apoptosis was attenuated by co-depletion of RPL11 (Fig. 17E). 
 Lastly, we tested the ability of RPL11 to rescue cell survival in response to the 
double strand break inducing chemotherapeutic Etopo.  Initially, Etopo was intended to 
be a specificity control as it is an inducer of p53-mediated apoptosis and is not known to 
induce nucleolar or ribosomal stress at low concentrations.  First, we verified by 
immunofluorescence that the dose chosen for rescue experiments, 1 µM, did not induce 
dispersion of NPM.  Indeed, the nucleolar localization of NPM was not altered by a 24 h 
treatment of 1 µM Etopo (Fig.18A).  Unexpectedly, knockdown of RPL11 attenuated 
apoptosis following Etopo treatment (Fig.18B,C).  Such a result suggested that Etopo 
could be impairing ribosomal biogenesis in the absence of nucleolar disruption.  
Interestingly, Etopo dose response revealed biphasic effects on pre-rRNA levels 
(Fig.18D).  In cortical neurons, the threshold for Etopo-induced nucleolar disruption and 
decrease in pre-rRNA has been confirmed to be between 10-25 µM. However, pre-rRNA 
levels were up at 0.3 and 1.0 µM (Fig.18D). Finally, western blot confirmed that RPL11 
was present in the nucleus after low dose Etoposide treatment (Fig.18E). 
Discussion 
 Our results suggest that RPL11 functions as a bona fide neuronal death mediator. 
Nucleolar disruption is a well characterized inducer of apoptosis in young neurons [106, 
198].  We demonstrate that knockdown of RPL11 is sufficient to increase survival 
following nucleolar stress induced by both genetic silencing of RNA Pol I and 
pharmacological treatment with CPT.  Moreover, we show that the effect was not due to 




Figure 18. Knockdown of RPL11 attenuates etoposide-induced apoptosis of cortical neurons. 
A, Immunofluorescence demonstrating that 1µM etoposide does not induce nucleolar stress.  B, 
Representative images depicting the criteria for quantification of neuronal apoptosis.  C, Quantification of 
neuronal apoptosis following 24 hours of 1 µM etoposide treatment.  Knockdown of RPL11 significantly 
increased neuronal survival.   D, Dose response depicting the effect of etoposide on pre-rRNA levels.  E, 
Western blot analysis demonstrating that RPL11 remains in the nucleus following treatment with 1 µM 




 rescue neuronal survival following inhibition of RNA Pol I.  Additionally, stoichiometric 
errors in ribosome assembly, produced by both knockdown of RPS6 and 5-FU treatment, 
were sufficient to induce apoptosis in the absence of nucleolar disruption.  Importantly, 
knockdown of RPL11 increased survival in both instances and in the case of 5-FU 
treatment produced a complete rescue of survival. 
 Unexpectedly, knockdown of RPL11 also increased survival following treatment 
with the double strand break inducing chemotherapeutic etoposide.  Surprisingly, pre-
rRNA levels increased in response to low dose etoposide treatment.  Taken together such 
findings suggest that concentrations of Etopo below the threshold for nucleolar disruption 
still impair ribosomal biogenesis.  It is tempting to speculate that Etopo-induced increases 
in pre-rRNA content are the result of inhibited pre-rRNA processing.  Interestingly, 
multiple proteins involved in ribosomal biogenesis have been described as putative 
substrates for the double strand break responsive protein, ataxia telangiectasia mutated 
[161].  Such interactions could underlie the effects of Etopo on pre-rRNA content.  
Alternatively, it is also plausible that RPL11 may be a more general mediator of cell 
death than originally anticipated.  In support of such a concept, Fumagelli et.al. (2012) 
demonstrated that increased translation of 5’ Terminal Oligopyrimidine Tract (5’TOP) 
mRNAs is sufficient to impair the stoichiometry of ribosomal components and induce 
ribosomal stress [64].  Therefore, a mechanism for inducing ribosomal stress without 
directly effecting RNA polymerase I or pre-rRNA processing does indeed exist. 
 The ability of ribosomal stress to induce apoptosis has not been documented in 
prior reports and may be a property unique to post mitotic neurons.  These results are in 
contrast to two prior studies which demonstrated ribosomal protein induced cell cycle 
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arrest and non-apoptotic accumulation of p53 [64, 125].  Using cell lines Fumagelli 
(2012) et.al. demonstrated that loss of an individual ribosomal protein other than RPL11 
or RPL5 induced p53 mediated cell cycle arrest [64].  Importantly, they found no 
evidence for apoptosis during their experiments.  Moreover, Kumazawa et.al. (2015) 
utilized a different approach, siRNA mediated knockdown of several pre-rRNA 
processing proteins, but came to similar conclusions.  They demonstrated that in the 
absence of RNA Pol I inhibition, impairment of processing was sufficient to induce 
accumulation of p53.  Interestingly, p53 remained in the unacetylated form and apoptosis 
did not occur [125].  They proceeded to show that once RNA Pol I was inhibited, the 
nucleolar protein MYBBP1A was released from the nucleolus and free to acetylate p53 
and induce apoptosis.  It is tempting to speculate that the pool of neuronal p53 is being 
modulated by an additional signaling pathway not active in cell lines.  Interestingly, 
nucleolar disruption induced apoptosis is developmentally restricted and occurs only in 
immature neurons [106, 198, 207].  It will be important for future studies to determine if 
the ribosomal stress apoptotic response is subject to similar restrictions. 
 Importantly, our results demonstrate that catastrophic nucleolar failure is not 
necessary for impaired ribosomal biogenesis to induce neuronal death.  Many 
neurodegenerative diseases have been proposed to involve nucleolar dysfunction, yet 
evidence suggesting full blown nucleolar stress is minimal or not existent.  AD is a 
prototypical example of such a condition.  Post mortem AD brain tissue has been 
reported to contain decreased ribosome content, increased ribosomal oxidative damage, 
and decreased protein synthesis capacity [47, 48].  Oxidative stress is a well characterized 
feature of Alzheimer’s disease, thus increased ribosomal damage and some amount of 
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decreased protein synthesis capacity is not entirely unexpected [42].  However, cells 
should contain homeostatic mechanisms for increasing ribosomal biogenesis under such 
conditions.  Our laboratory has identified increased methylation of the rDNA promoter in 
post mortem AD brain tissue [206].  Such a phenotype is believed to be a biomarker of 
decreased transcriptional activity, and suggests decreased ribosomal biogenesis during a 
time when cellular demands are expected to be high [238].  When considered together the 
trio of decreased total ribosome content, increased ribosomal damage and increased 
rDNA promoter methylation suggest an AD-associated homeostatic failure of ribosomal 
biogenesis.  The finding that RPL11 functions as a stress mediator in the absence of 
nucleolar disruption suggests that it may indeed play a role in AD-associated 
neurodegeneration. 
 The translational relevance of RPL11-induced neuronal death may be of 
importance for C9ORF72 hexanucleotide repeat expansion associated ALS/FTD (C9) 
and poly glutamine diseases (PolyQ), such as Huntington’s- and Machado-Joseph’s- 
Disease.  These diseases have been proposed to contain RNA and protein species which 
have a direct impact on nucleolar function [79, 129, 135, 244, 245].  Interestingly, they 
may be associated with different stress responses.  PolyQ derived RNAs and proteins 
appear to induce a primarily nucleolar stress as inhibition of RNA Pol I has been 
demonstrated by multiple mechanisms [135, 244, 245].  Alternatively, C9 toxicity has 
been proposed to involve inhibited pre-rRNA processing, which suggests a 
predominantly ribosomal stress.  Interestingly, the morphology of C9 nucleoli appears 
highly irregular and bulbous similar to 5-FU treatment [79].  Our findings suggest that 
RPL11 may be a highly desirable target for future PolyQ and C9 studies. 
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 It will be important for future studies to address the possibility of other ribosomal 
proteins as stress mediators. Fourteen ribosomal proteins have been documented to bind 
MDM2 to date and experts predict this number will grow [114].  The physiological 
relevance of many of these has been debated given that free ribosomal proteins are 
rapidly degraded by the proteasome [25, 131].  Although, several key points argue for 
their relevance.  First, MDM2-Ribosomal protein interactions happen at several discrete 
locations.  Such specificity argues against these interactions being non-physiological.  
Moreover, three of these ribosomal proteins have been documented to modulate p53 
mediated transcription towards different target genes [40].  Thus, the functions of these 
14 MDM2 binding ribosomal proteins may be highly relevant for stress responses.  
Lastly, 11 ribosomal proteins were identified as potential tumor suppressors in a 
zebrafish-based screen [4].  Therefore, a wealth of additional ribosomal proteins are 
potential targets for future investigations. 
 In conclusion, our results demonstrate that RPL11 is bona fide neuronal death 
mediator in response to both nucleolar stress and ribosomal stress.  In addition, we 
demonstrate that catastrophic nucleolar failure is not necessary for ribosomal protein 
mediated apoptosis.  Lastly, we provide preliminary evidence suggesting that etoposide 
may be a novel inhibitor of pre-rRNA processing.  Hence, RPL11 is an intriguing target 





Restatement of Key Findings 
 These studies focused on elucidating the role of nucleolar dysfunction, including 
both canonical nucleolar stress and atypical forms of dysfunction, in neuronal death and 
degeneration. 
 In Chapter II, I report that genomic rDNA content is unstable in the Dementia 
with Lewy Bodies (DLB) brain and is not the result of altered rDNA promoter 
methylation.  These studies were necessitated by prior Hetman laboratory reports 
demonstrating increased rDNA promoter methylation and gene content in the 
Alzheimer’s disease (AD) brain [206].  Such findings raised two possibilities.  First, AD 
could potentially involve a disease-associated amplification of rDNA genes or second, an 
AD-associated increase in promoter methylation could be reducing the aging-associated 
loss of rDNA genes.  Loss of rDNA is a well-accepted source of senescence in yeast and 
in the 1970s was proposed to occur in the mammalian brain by Bernard Strehler [105].  
However, subsequent studies did not confirm such a phenomenon [68, 205].  Despite a 
general consensus that Strehler’s hypothesis was sufficiently debunked; the co-incidental 
occurrence of increased methylation and increased copy number in elderly samples was 
highly intriguing.  Thus, I deemed it necessary to revisit Strehler’s hypothesis with more 
modern technology as a means to discriminate between these two potential hypothesizes.  
Therefore, I probed rDNA content in post mortem parietal cortex tissue from both young
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 and old individuals.  No aging-associated loss of rDNA content was found.  Next, I 
addressed if increased rDNA content was specific to AD or a general feature of 
neurodegeneration by probing rDNA content in the DLB parietal cortex using genomic 
qPCR.  Indeed, DLB samples contained more rDNA copies than elderly controls.  Lastly, 
I probed the DLB rDNA promoter for increases in methylation and found it to be 
unchanged.  Thus, in the brain, increased genomic rDNA content is not unique to AD as 
it was also found in DLB. Conversely, changes in promoter methylation appear to be an 
AD specific condition. 
 In Chapter III, I assessed the integrity of several markers of nucleolar dysfunction 
in response to increasing PMI.  I report relatively modest decreases in pre-rRNA for up to 
12 h.  Transcription of pre-rRNA is believed to be sensitive to cellular energy levels and 
the supply of available nutrients [76, 182, 260].  Thus, significant declines in 47S pre-
rRNA content would be expected under ischemic conditions.  Such a modest effect 
suggested the simultaneous inhibition of both transcription and processing.  Indeed, I 
demonstrated that following pharmacological inhibition of pre-rRNA synthesis, energy 
deprivation prolongs the half-life of pre-rRNA.  Therefore, my results suggest that the 
dramatic declines in pre-rRNA which would be expected to occur during ischemia-
induced energetic failure are blunted by the simultaneous inhibition of processing.  
Additionally, I report that punctate nucleolar localization of nucleophosmin was detected 
in all cells though PMIs of 12 h, despite a percentage of cells having accumulation of 
nucleophosmin in the perikaryon and proximal neurites.  Lastly, rDNA promoter 
methylation and genomic rDNA content were unaffected through PMIs of up to 12 h 
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 In Chapter IV, I report the ability of RPL11 to function as a bona fide death 
mediator in primary cortical neurons.  Overexpression of RPL11 was sufficient to 
augment p53-mediated transcription.  Knock down of RPL11 significantly increased 
neuronal survival in response to nucleolar stress which was induced by both genetic 
manipulation and pharmacological means.  Moreover, I demonstrated that the 
chemotherapeutic agent 5-FU is an inducer of ribosomal stress in primary cortical 
neurons.  Such a conclusion is based on its ability to significantly impair pre-rRNA 
processing and induce p53 in the absence of RNA polymerase I inhibition.  Importantly, 
canonical nucleolar stress was not necessary for RPL11 induced death as its knockdown 
increased survival in response to ribosomal stress induced by knockdown of RPS6 and 
treatment with  5-FU.  Lastly, RPL11 knock down unexpectedly increased neuronal 
survival in response to etoposide treatment and preliminary data suggests that etoposide 
may increase pre-rRNA levels at low doses.  Taken together, these findings suggest that 
low dose etoposide may be a previously unreported inducer of ribosomal stress 
Impact 
 In chapter II, I demonstrated genomic instability in the dementia with Lewy 
bodies brain. Genomic instability in the mature, non-neoplastic mammalian brain is a 
newly emerging research topic with only a small number of documented cases.  To the 
best of my knowledge, evidence for such a phenomenon is limited to three specific 
research areas, activation of Line-1 (L1) retrotransposons, neurodegenerative disease-
associated telomere shortening, and the rDNA studies of myself and Dr. Pietrzak.  Thus, 
while I am not the first to document such a phenomenon, my work still provides 
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significant weight of evidence support for genomic instability playing a role in human 
neurodegenerative diseases. 
 Additionally, the pro-neurodegenerative potential for nucleolar stress must also be 
considered.  While I speculate in chapter II that expansion of rDNA gene content could 
potentially blunt the DNA damage response, it is important to consider that the ribosomal 
stress response is centered on stoichiometric imbalances.  However, given the intricate 
regulation of RNA polymerase I, expansion of rDNA content alone is presumably not 
sufficient to induce stoichiometric errors in ribosomal components.  Speculation aside, I 
have, at the very least, demonstrated a significant disease-associated alteration of a 
genomic region which has been proposed by some to be a major regulator of p53 [23]. 
 In chapter III, I assessed the stability of nucleolar stress mediators in post mortem 
tissue.  While post mortem ischemia altered the localization of a minor portion of NPM, 
100% of the cells examined contained punctate NPM staining.  Thus, at least for animal 
models, binary assessment of nucleolar morphology appears to be highly reliable in post 
mortem brain tissue.  Such results strengthen the findings of others who have quantified 
nucleolar disruption in post mortem specimens of brain tissue to uncover PD-, HD- or 
AD-associated nucleolar stress. 
 While not common in recent years, studies utilizing an NPM localization index 
can be found in the literature.  As interest in nucleolar stress is currently on the rise, it 
would not be surprising to see this method re-emerge in the near future.  Similar to the 
NPM localization index, Kwon et.al. has claimed nucleolar stress in cell culture models 
despite the presence of punctate nucleoli [129].  Such a claim was based on a portion of 
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NPM being released into the nuclear compartment, despite the retention of punctate 
nucleoli.  While such a criterion of nucleolar stress may work in cell culture models, my 
results suggest that it may not be reliable in human tissue due to significant effect of post 
mortem interval. . 
 Additionally, I assessed the post mortem stability of three other nucleolar stress 
markers, 47S pre-rRNA content, rDNA content, and rDNA promoter methylation.  
Importantly, I found that rDNA content and rDNA methylation were not significantly 
altered during the 12 hour analysis.  Such findings help to strength the results of myself 
and Dr. Pietrzak who have quantified these parameters in post mortem tissue [81, 206].  
This finding strongly suggests that the effect of post mortem interval on our results is 
relatively minimal.  On the other hand, 47S pre-rRNA content was significantly 
decreased by 12 hours, despite the magnitude of decline being surprisingly low.  
Interestingly, select regions of the transcript appeared to have increased stability.  
Therefore, I propose that 47S pre-rRNA measurements are potentially feasible in post 
mortem tissue given the slow rate of decline, but such measurements would require 
tightly grouped PMIs and carefully designed amplicons to minimize the impact of PMI. 
 While this particular study focused on post mortem ischemia inducing energetic 
failure in brain tissues, a much broader conclusion can also be drawn from my studies. 
Namely, impairment of pre-rRNA processing can mask the inhibition of RNA 
polymerase I.  This implies that stoichiometric imbalances in ribosomal components and 
induction of the ribosomal stress response can occur regardless of changes in nucleolar 
morphology.  Such a condition is of great importance as there is considerable evidence 
for abnormal nucleolar function in many neurodegenerative conditions, despite the 
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persistence of NPM staining in the nucleolus.  Therefore, activation of the ribosomal 
stress response cannot be excluded solely based on the staining of morphological 
markers. 
 In chapter IV, I demonstrated that RPL11 is a bona fide mediator of nucleolar 
stress, ribosomal stress and most importantly neuronal death in primary cortical neurons.  
While similar results have been described in other cell types such as immortalized cell 
lines and liver tissue from in vivo models, I am the first to validate RPL11 as a death 
mediator in the nervous system.  Elucidation of stress mediators is essential for assessing 
the contribution of nucleolar- and ribosomal stress to human neurodegenerative disease.  
Thus, this is a fundamental discovery that myself and others can build upon in future 
studies. 
 Next, we demonstrated that the DNA double strand break-inducing 
chemotherapeutic etoposide may harness ribosomal stress to activate p53-mediated 
apoptosis. Interestingly, we identified a biphasic response with increased 47S pre-rRNA 
and no nucleolar stress at etoposide doses below 1µM at which apoptosis was attenuated 
by depletion RPL11 When considered together these findings suggests that low 
frequency DNA double strand breaks engage the ribosomal stress response independently 
of the RNA polymerase I inhibition which is seen at significantly higher doses of 
etoposide. 
 While evidence for full blown nucleolar stress is rare, there is considerable 
evidence suggesting perturbation of nucleolar function, nucleolar insufficiency, and 
nucleolar hypertrophy in many neurodegenerative and neurodevelopmental diseases.  
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Importantly, I demonstrated that knockdown of RPL11 rescues neuronal survival in 
response to numerous apoptotic insults, several of which do not disperse NPM or inhibit 
RNA polymerase I.  This strongly suggests that nucleolar stress is sufficient, but, 
importantly, is not necessary for RPL11-mediated neuronal death.  Therefore, pro-
apoptotic ribosomal stress may indeed be active in conditions in which nucleoli appear 
unaffected.  
Limitations and Alternative Interpretations 
 In Chapter II, the biggest limitation for drawing conclusions is the descriptive 
nature of the study design.  While I speculate on the potential consequences of increased 
rDNA content in this chapter, the true biological relevance is unknown.  To address this 
situation, transgenic mice with variable rDNA content would have to be generated.  Such 
mice could be utilized to test the working model which speculated that increased rDNA 
content increased the resistance to DNA damage induced cell death. 
 The lack of information regarding the responsible cell type is also a major 
limitation to the interpretation of this study.  Importantly, such information could allow 
for the generation of more accurate hypotheses and better shape future studies.  For 
instance, if this is a glial phenomenon I would hypothesize that glial-specific rDNA 
expansion is a mechanism for the rapid expansion of these cells which occurs during 
gliosis.  On the other hand, if this is a neuron-specific rDNA instability, I hypothesize 
that neuron specific rDNA expansion is a mechanism to increase cellular reliance when 
faced with increasing amounts of DNA damage.  Similarly, knowledge regarding the cell 
cycle status of affected cells, i.e. mitotic vs post-mitotic, would be of considerable value 
when attempting to determine the mechanism of rDNA amplification.  Thus, the lack of 
111 
 
an identified cell type severally impairs the ability to assess the biological significance of 
rDNA amplification. 
 Some critics may have a strong preference for southern blot and would claim that 
the choice of qPCR is a limitation to this study.  While I agree that a southern blot 
analysis would provide weight of evidence support to strengthen my claims, I would 
argue that it is simply not necessary.  I conducted numerous quality control measures to 
verify the accuracy of my results.  First, as the gene specific stability of DNA in post 
mortem tissue is unknown I employed two separate reference genes for normalization, 
one multi-copy and one single copy.  Importantly, both normalizers produced highly 
similar results.  Therefore, my results do not appear to be skewed by instability of the 
reference gene.  Second, I measured the rDNA unit at three separate locations.  
Importantly, all three amplicons produced comparable results.  Third, given that all three 
PCR amplicons are physically linked in the same rDNA unit, there should a high degree 
of correlation when comparing rDNA content from various amplicons of the same 
individual if measurements are accurate and indeed, the regression analysis for 18S vs 
28S was R
2
=0.81.  Fourth, I demonstrated that DNA template methylation levels do not 
skew qPCR results.  Thus, while a southern blot analysis would complement my results 
and provide weight of evidence support it is unnecessary as my numerous quality control 
measures suggest this method is indeed sufficient. 
 In this chapter II also assessed changes in methylation of the rDNA promoter 
using two separate methods, bisulfite clonal sequencing and qPCR utilizing genomic 
DNA cleaved by the CpG methyl sensitive restriction endonuclease HpaII (HpaII).  
Neither method is perfect as both contain limitations, but importantly they complement 
112 
 
each other well.  Bisulfite sequencing provides information about every CpG in the 
promoter and can show trends contained within the same clone, but the analysis is limited 
to finite a number of clones.  On the other hand, HpaII assesses only one CpG and is 
applicable to only a fraction of CpGs.  However, the major benefit is that this method 
theoretically probes 100% of loci contained within a sample.  These two methods in 
combination strongly suggest that the rDNA promoter does not contain increased 
methylation in the DLB brain.  Regarding the biological significance of promoter 
methylation, this epigenetic modification is merely a biomarker of recent RNA Pol I 
activity and not a direct measurement of RNA Pol I activity.  Thus, changes in 
methylation do not guarantee changes in pre-rRNA synthesis.  To further characterize 
RNA Pol I activity in post mortem tissue chromatin immunoprecipitation (CHIP) could 
be performed to assess levels of rDNA promoter occupancy.  Moreover, the data 
contained in chapter III suggests that pre-rRNA levels could also be used as a marker of 
RNA polymerase I activity.  
 In Chapter III, I assessed the stability of nucleolar stress markers in response to 
increasing PMI.  All findings are based on experiments conducted in adult rats or rat 
primary cortical neurons in culture.  Despite the fact that I utilized both in vivo and in 
vitro methods, one major limitation to this study is the lack of assessments made in 
human tissue.  It is not guaranteed that my findings will translate to the human brain.  For 
example, I conclude that large quantities of NPM are retained in the nucleolus through 
PMIs up to 12 h.  Conversely, a study conducted by Rieker et.al. demonstrated that some 
percentage of neurons in post mortem control tissues did not contain visible punctate 
nucleoli [214].  However, it is important to consider that this study was restricted to an 
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elderly population, thus the lack of punctate nucleoli in some neurons may be related to 
senescence and not post mortem degradation [214]. 
 Two other conclusions in this chapter are based solely on qRT-PCR 
measurements.  First, I conclude that pre-rRNA is unstable in response to increasing PMI.  
Second, I conclude that pre-rRNA processing is inhibited by energy deprivation.  The 
validity of both of these claims could be greatly strengthened by including a northern blot 
analysis.  Moreover, this method would also provide in depth information regarding the 
stability of specific 47S pre-rRNA fragments in response to increasing PMI and acute 
energy failure.  Such information could allow for the design of qRT-PCR amplicons 
which display optimum stability in post-mortem tissue.  Thus, the use of additional 
methods could not only strengthen this conclusion, but also provide practical information 
to improve the design of future experiments. 
 Additionally, we speculate that the loss of pre-rRNA at later PMIs is due to non-
specific energy independent RNases.  Such speculation is based on the ubiquitous nature 
of energy independent RNases and the rapid decline of ATP which is known to occur in 
post mortem tissue.  However, such a condition cannot be determined by only qRT-PCR.  
An alternative explanation is that some amount of pre-rRNA processing enzymes retain a 
portion of their activity in the absence of ATP.  A northern blot analysis could address 
this issue as the retention of specific fragments would suggest cleavage by the canonical 
processing pathway, while the absence of specific fragments and a smear pattern on these 
blots would suggest non-specific degradation. 
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 In chapter IV, I begin by proposing that nucleolar stress and ribosomal stress are 
separate but partially overlapping stress pathways.  Nucleolar stress is sufficient but not 
necessary to induce ribosomal stress.  The two major conclusions in this chapter are 1-
RPL11 is a mediator of both the nucleolar stress response and the ribosomal and, 2- 
Ribosomal stress induces apoptosis in immature cortical neurons.  Interestingly, the latter 
result differs from other studies which suggest ribosomal stress induces cell cycle arrest, 
premature induction of senescence and in general a non-apoptotic accumulation of p53 
(Kumazawa et al. 2015; Fumagalli et al. 2012; K. Nishimura et al. 2015; Fumagalli et al. 
2009). 
 One important consideration to explain such a discrepancy is the choice of models 
utilized in our studies.  The Kimura laboratory utilized several cell lines including, MCF-
7, WI-38, and MEFs (K. Nishimura et al. 2015; Kumazawa et al. 2015).  The Thomas 
laboratory utilized the livers of transgenic RPS6 knock out mice along with the A549 and 
U2-OS cell lines (Fumagalli et al. 2012; Fumagalli et al. 2009).  I utilized rat primary 
cortical neurons.  The most likely explanation for the difference in findings is that 
apoptotic outcome of ribosomal stress is cell type specific. It may also be dependent on 
maturation stage as adult neurons do not undergo apoptosis in response to nucleolar 
stress.  Thus, there is already evidence that neurons are indeed unique with regard to 
ribosomal protein-mediated death.  However, for scientific stringency, the limitations of 
the model should also be considered. 
 The finding that ribosomal stress induces apoptosis is based on experiments 
conducted exclusively in rat primary cortical neurons.  Ribosomal stress was induced 
using shRNA-mediated knockdown of RPS6 and treatment with 5-FU.  Moreover, data 
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generated by myself and Dr. Smith suggest that low dose etoposide is a previously 
unidentified inducer of ribosomal stress.  Thus, if we are indeed correct about etoposide, 
we used 3 separate inducers of ribosomal stress.  Importantly, all 3 inducers are 
mechanistically very different.  However, each method does have drawn backs.  For 
example, etoposide is a well-documented DNA damaging agent.  Thus, even at low doses 
which do not inhibit RNA polymerase I the resulting apoptosis is most likely a 
combinatorial effect of DNA damage and possibly pre-rRNA processing impairment.  
Moreover, 5-FU is also multi-mechanisms, suggesting that this approach may also 
include combinatorial effects [23].  Lastly, all experiments utilized shRNA-mediated 
knockdown of RPL11 to rescue survival. 
 As all key experiments of Chapter IV relied on shRNAs, it is important to 
consider the drawbacks of this approach.  For example, the act of expressing shRNAs 
may be toxicic due to activation of cell intrinsic anti-viral response.  Primary neurons 
appear to be disproportionally sensitivity to shRNA-mediated toxicity relative to other 
cell types [160, 164].  In support of this concept, when comparing shRNA transfected 
neurons to those which are untransfected or transfected with a plasmid expressing a non-
toxic protein such as green fluorescent protein (GFP) or td-tomato, considerably lower 
dosages of DNA damaging agents are required to produce equivalent levels of cell death 
(unpublished observations).  Moreover, the effect of shRNA toxicity in primary neurons 
is evident when considering the kinetics of 5-FU induced apoptosis.  Dr. Vashishta 
characterized the model of 5-FU induced death in primary cortical neurons and 
demonstrated that 5-FU (10 µM) induced death is not detectable at 48 hours.  At 72 hours 
approximately 80% death was detected.  Surprisingly, in shRPL11-mediated rescue 
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experiments the same dose of 5-FU produced approximately 80% death by 36 hours.  
Thus, the mere presence of control shRNAs approximately doubled the rate of 5-FU 
induced death.  Therefore, at least in the case of primary cortical neurons, the 
contribution of shRNA-associated stress may synergize with ribosomal stress to kill.  
Such a condition should not affect the finding that RPL11 is a bona fide stress mediator; 
however, it is possible that the induction of apoptosis represents the sum of two separate 
stressors, ribosomal stress and shRNA-induced toxicity.  I will further address this 
possibility in the Future Directions section of this chapter. 
 Lastly, the in vitro approach utilized in chapter IV is a potential limitation.  It will 
be important for future studies to validate if the major conclusions generated in this 
chapter translate to whole animal studies.  Potential models for pursing in vivo studies 
will be described in the future directions section. 
Future Directions 
Validate the claim of ribosomal stress induced neuronal apoptosis using alternative 
approaches and in vivo models. 
 As described in the limitations section of this chapter, shRNA-mediated induction 
of ribosomal stress has been successfully used in other cell types, but the potential exists 
for confounding toxicities in neuronal models.  As I am specifically, interested in cell 
death pathways, such a condition could be problematic.  Therefore, with scientific 
stringency in mind, I propose to build upon my initial findings by further testing my 
hypothesis in several additional models, both in vitro and in vivo. 
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 A number of potential approaches exist to induce ribosomal stress in primary 
cortical neurons without using shRNA-mediated knock downs.  Nishimura et.al. (2015) 
demonstrated that loss of individual pre-rRNA processing proteins is sufficient to induce 
ribosomal stress.  While they used shRNA-mediated knock down of Ribosome 
Biogenesis Regulator Homolog (RRS1), Dyskeratosis Congenita 1 (DKC1), and 
Ribosomal Processing Protein 5 (RRP5), a similar phenotype can be obtained by 
expressing dominant negative (DN) mutants of other pre-rRNA processing proteins.  
Importantly dominant DN mutants have been described in the literature for both 
Pescadillo Ribosomal Biogenesis Factor 1 (PES1) and Block Of Proliferation 1 (BOP1) 
[73, 204].  Together along with WD Repeat Domain 12(WDR12) these three proteins 
form the PeBoW complex which is essential for pre-rRNA processing.  Thus, through the 
use of dominant negative variants I can easily induce ribosomal stress in primary neurons 
without using shRNAs or concern for off-target pharmacology.  Moreover, as two 
components of this complex are already validated in their dominant negative form, this 
controls for the possibility of promiscuous protein-protein interactions as both DN-BOP1 
and DN-PES1 would be expected to produce the same phenotype. 
 Additionally, there are several other potential approaches for inducing ribosomal 
stress without shRNAs in the unexpected event that DN-BOP1 and DN-PES1 do not 
produce ribosomal stress in primary cortical neurons.  In other cell types, overexpression 
of TIF-1a is sufficient to increase rRNA transcription, nucleolar rRNA content, and the 
accumulation of p53 and p21 [187].  Thus, this may be another viable alternative.  
Additionally, mutant RPS19
R62W
 has been proposed to be a dominant negative ribosomal 





) is known to induce ribosomal stress [187].  However, it 
is important to consider that HRAS
G12V
 would alter cell signaling well upstream of 
ribosomal stress and would be expected to have multiple effects on cell signaling.  In 
summary, there are many additional options for further in vitro validation of ribosomal 
stress as an inducer of neuronal apoptosis. 
 Another major consideration is that my findings are limited to only in vitro 
experiments.  To address this deficit, I propose the generation of a tamoxifen-inducible 
ribosomal stress mouse model.  Nucleolar stress has been successfully modeled using a 
similar approach.  The Schutz laboratory has taken a transgenic mouse containing floxed 
TIF-1a alleles and crossed it with tamoxifen inducible cre-recombinase mice under the 
control of several different neuron specific promoters [122, 214].  This approach could be 
adapted for ribosomal stress by substituting a single ribosomal protein for TIF-1a.  The 
Thomas laboratory has generated a transgenic mouse with floxed RPS6 alleles [64].  This 
mouse could be crossed with CaMKCreERT2 mice to generate an inducible neuron-
specific ribosomal-stress-associated transgenic mouse model. 
 Such a transgenic mouse model could be used to address a number of concerns.  
First, it could be used as another mechanism to validate the claim of ribosomal stress 
induced neuronal apoptosis.  Second, it is important to determine if my results translate to 
in vivo conditions.  Such a deficit greatly limits the limits the impact of my findings.  
Lastly, this model could also be utilized to test any potential pharmacological 
interventions. 
Determine in greater depth the mechanisms of RPL11-mediated neuronal apoptosis 
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 Many questions remain unanswered regarding the mechanisms behind RPL11-
mediated neuronal apoptosis.  The next logical assessment would be to determine if 
neuronal ribosomal stress induced apoptosis is p53-mediated.  This outcome is highly 
expected, as neuronal nucleolar stress is p53-mediated as is ribosomal stress in cell lines, 
but still requires verification. 
 If neuronal ribosomal stress is indeed p53-mediated, the next step would be to 
determine if the response requires MDM2.  The involvement of MDM2 in neuronal 
nucleolar/ribosomal stress can be assessed in several ways, both in vivo and in vitro.  
First, if RPL11’s effects are indeed MDM2-mediated, 5-FU and CPT would be expected 
to induce RPL11-MDM2 protein-protein interactions which could be verified by co-
immunoprecipitation. 
   Second, the protein Proline Rich AKT Substrate (PRAS40) is a negative 
regulator of 5S RNP-MDM2 interactions and as such, its overexpression would be 
expected to decrease 5-FU induced apoptosis [87].  Third, the effects could be verified in 
vivo with the MDM2-C305F transgenic mouse line.  The C305F mutation is located at 
the first amino acid in the zinc finger just outside the central acid region and disrupts the 
binding of both RPL11 and RPL5 [114, 142].  Interestingly these mice retain the p53-
mediated response to DNA damage but not Act-D-induced nucleolar stress.  Therefore, if 
the neuronal ribosomal stress response is RPL11-MDM2 mediated it should be 
inactivated in these mice. 
 Third, another important consideration will be to determine if RPL11 is 
functioning independently or in conjunction with other ribosomal proteins.  RPL11 and 
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RPL5 are known to co-localize with the 5S rRNA in the 5S ribonucleoprotein particle (5S 
RNP), a subcomponent of the large ribosomal subunit.  Despite the fact that at least 14 
ribosomal proteins possess the ability to bind MDM2, the 5S RNP appears to be the 
major stress effector in other cell types as several papers have demonstrated that it’s three 
components are essential for p53 induction [25, 49, 64].  Thus, it is tempting to speculate 
that the entire 5S RNP may potentially be the effector molecule in neurons.  Under such 
conditions knockdown of RPL5 or inhibition of RNA polymerase III would be expected 
to phenocopy the effect of RPL11 knockdown. 
 Lastly, if RPL11’s effects are independent of the 5S RNP, MDM2 or p53 several 
other mechanisms are potentially possible.  For instance, RPL11 has been shown to bind 
the promoters of p53 target genes and MDMX [154].  Thus, RPL11 can still potentially 
modulate p53 in the absence of MDM2 interaction.  Additionally, while RPL11 does not 
directly bind p53, it has been reported to bind TAp73, suggesting this could be a potential 
alternative mechansism [266].  Moreover, RPL11 is also known to interact with NEDD8 
[154].  NEDD8 presents an especially interesting possibility as it has been linked to non-
p53-mediated apoptosis, p53-mediated senescence, and pre-rRNA processing [13, 248].  
RPL11 is also known to have interactions with MYBBP1A and the tumor suppressor 
Alternate Reading Frame (ARF), although in both cases it’s believed to be assembled in 
the 5S RNP [128, 225].  Therefore, there are a number of potential mechanisms if the 
canonical pathway is not active in neurons. 




 It will be important for future studies to address the potential role of other 
ribosomal proteins in response to nucleolar and ribosomal stress.  Ribosomal proteins 
other than RPL5 and RPL11 present an interesting scenario.  On one hand, the translation 
of ribosomal proteins is believed to exceed the production of other ribosomal 
components, and as such excess ribosomal proteins are rapidly degraded by the 
proteasome [131].  Moreover, studies on nucleolar stress have reiterated these early 
findings and suggest that RPL5 and RPL11 escape degradation by dimerizing to one 
another [25].  Thus, this has led some to question the physiological relevance of free 
ribosomal proteins.  In opposition to this hypothesis, numerous extra-ribosomal functions 
of ribosomal proteins have been described in the literature [251].  Thus, the numerous 
reports of extra-ribosomal functions strongly suggest that some quantity of free ribosomal 
proteins must escape degradation.  Additionally, 12 other ribosomal proteins in addition 
to RPL5 and RPL11 have been documented to bind and inhibit MDM2 [114].  Moreover, 
these 12 ribosomal proteins do not all bind in the same location on MDM2.  Such 
specificity suggests that they cannot be disregarded as simple acid-base interactions.  
Intriguingly, overexpression of three of these ribosomal proteins, RPL37, RPS15 and 
RPS20, produced differential effects on the expression of several p53 target genes [40].  
Given such results it would be tempting to explore the combinatorial effect of certain 
ribosomal proteins.  Thus, more work is needed to determine the legitimacy of other 
ribosomal protein-mediated mechanisms. 
 Lastly, 11 ribosomal proteins have been linked to peripheral nerve sheath tumor 
formation in zebra fish.  As a majority of tumor suppressor genes are recessive lethal, the 
authors screened several hundred lines of zebrafish which were heterozygous for a 
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recessive embryonic lethal mutations [4].  Interestingly of the 12 total hits, they identified 
11 which were ribosomal proteins.  Importantly, only two of these ribosomal proteins 
identified in this screen are known binders of MDM2.  This suggests that the other 9 
ribosomal proteins may produce their effects by an alternative mechanism. 
Determine the role of nucleolar- and ribosomal-stress in CIPN and Chemobrain. 
 After determining the basic mechanisms of neuronal ribosomal stress in rat 
primary cortical neurons, and then validating these mechanisms in an in vivo model, the 
next logical step would be to determine the contribution of ribosomal stress to disease 
relevant models.  In chapter I, I summarized the evidence which suggests nucleolar stress, 
via direct inhibition of RNA Polymerase I, or ribosomal stress, via inhibition of 47S pre-
rRNA processing, are potential mechanisms for both CIPN and Chemobrain.  
Admittedly, the evidence for such a condition is disjointed.  There is a significant amount 
of evidence demonstrating that numerous chemotherapeutics negatively alter nucleolar 
function.  There is also a significant amount of evidence suggesting that robust nucleolar 
output is necessary for such fundamental processes as neuronal growth, maintenance and 
recovery after injury [72, 115, 116, 226, 231].  It is also curious, that in the case of CIPN 
the largest neurons appear to be disproportionally affected as this population requires the 
greatest rates of ribosomal biogenesis.  Therefore, I propose that many common 
chemotherapeutics induce CIPN and chemobrain by induction of nucleolar stress and/or 
ribosomal stress. 
 Such a hypothesis could be tested in several ways.  First, wild type rodents could 
be given chronic administration of pharmacologically relevant doses of several 
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chemotherapeutics associated with CIPN and/or chemobrain.  The presence of canonical 
nucleolar and/or ribosomal stress markers could then be quantified at various time points 
throughout the course of administration.  Moreover, the induction of these stress markers 
could then be correlated against the onset and severity of symptoms, including those 
associated with learning and memory deficits, behavior, electrophysiology, and 
histological changes.  Second, for proof of principle, cre-lox technology could be used to 
generate inducible sensory neuron specific RPS6 knock out mice.  Such mice could then 
be tested for sensory deficits which phenocopy human and rodent CIPN.  Lastly, the 
Zhang laboratory has generated a transgenic mouse containing a mutation in MDM2 
which prevents its interaction with ribosomal proteins.  If my hypothesis is correct, such a 
mouse should have significantly reduced symptoms or possibly even be immune to 
CIPN.  However, it is important to consider that while these mice would be expected to 
have a blunted stress response, they would still have decreased ribosomal biogenesis.  It 
is currently unclear how much each component (i.e. stress response vs ribosomal deficits) 
contributes to the overall phenotype. 
Assess the role of ribosomal stress in Amyotrophic Lateral Sclerosis (ALS) and 
Frontotemporal Dementia (FTD). 
 The results generated by my co-workers and I suggest that the impairment of pre-
rRNA processing is an inducer of ribosomal stress, ribosomal stress is an inducer of 
apoptosis in primary neurons, and that RPL11 mediates this apoptotic response.  While 
many neurodegenerative diseases have evidence for nucleolar abnormalities, in some 
cases it is unclear if such a phenotype is a cause or alternatively, an effect of 
neurodegeneration.  However in the case of C9ORF72 hexanucleotide expansion-linked 
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ALS and FTD, there are numerous reports suggesting that nucleolar and ribosomal stress 
occur early in the disease process.  Thus, C9ORF72-linked ALS and FTD appear to be 
the best option for future studies centered on neurodegenerative disease. 
 Hexanucleotide repeat expansions in the C9ORF72 gene are the most frequent 
cause of both ALS and FTD [246].  Recent reports describe a mechanism whereby RNAs 
originating from this repeat expansion region are transcribed by RAN translation 
generating several types of dipeptide repeats (DPRs) [252].  The two arginine rich DPRs 
are believed to mimic the binding properties of many RNA processing proteins and have 
been proposed to irreversibly bind RNA processing bodies [129, 252].  This concept is 
supported by evidence demonstrating impairment of pre-rRNA process and mRNA 
splicing [129, 210].  I speculate that 5-FU induced impairment of pre-rRNA processing 
and DPR-induced impairment pre-rRNA processing converge at the same endpoint, 
stimulation of the ribosomal stress response.  Thus, as shRPL11 produced a complete 
rescue of neuronal survival in response to 5-FU, RPL11 may also be a significant 
mediator of C9 pathology.  Interestingly, others have proposed that C9 RNAs inhibit 
RNA Polymerase I through inhibition of nucleolin.  Thus, it appears that C9 may inhibit 
ribosomal biogenesis at multiple points. 
 First, I propose to better characterize ribosomal stress in C9.  Despite several 
studies depicting rRNA processing deficits in C9, there are no reports legitimately 
characterizing impairments of ribosome synthesis or activation of the ribosomal stress 
response in post mortem tissue, transgenic animals, or in vitro models.  Moreover, the 
data demonstrating mRNA splicing deficits is considerably stronger than those depicting 
impaired pre-rRNA processing [129, 210].  Thus, it will be important to determine if post 
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mortem tissue , animal models, or cell culture models contain common markers of 
aberrant ribosomal biogenesis such as increased p53, decreased ribosome content, 
decreased protein synthesis and decreased mTOR signaling, RP-MDM2 interaction, etc. 
[214].  Moreover, a northern blot based analysis of pre-rRNA processing using RNA 
from a C9 animal model or possibly an iPSC derived neuronal culture is necessary to 
truly substantiate the claims of impaired pre-rRNA processing. 
 If indeed C9 is found to involve dysfunctional ribosomal biogenesis and induction 
of ribosomal stress, I propose crossing C9 transgenic mice with the MDM2-C305F 
mouse line.  As I have demonstrated that RPL11 is a mediator of ribosomal stress, the 
inability of RPL11 to bind MDM2 would be expected to significantly reduce a large 
portion of C9 related pathology.  However, the one caveat to this approach is that to date, 
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